**Funding opportunities for southern Ontario organizations**

On February 27, 2019, over $1 billion was announced for FedDev Ontario to continue driving innovation and growth in the region over the next six years. Recognizing the vital role smaller and rural communities play in the region’s economy, as well as their unique needs and opportunities, FedDev Ontario is dedicating $100 million of this new funding to support projects in rural southern Ontario.

FedDev Ontario is now accepting applications under three simplified funding streams that are easy to navigate, and have been designed to meet the needs of our innovators, job creators and communities.

FedDev Ontario is looking for innovative projects in southern Ontario that will:

- Increase the number of high-growth firms.
- Strengthen key clusters and build on areas of regional innovation strength.
- Increase the commercialization of new and innovative technologies, products or processes.
- Increase business investments in the adoption/adaptation of leading-edge technologies.
- Create and maintain highly skilled jobs.
- Increase the value of exports.
- Promote inclusive growth and participation of traditionally underrepresented groups such as women, Indigenous and young entrepreneurs.
- Strengthen opportunities and networks to drive growth, and support the attraction and retention of businesses and talent to southern Ontario’s smaller communities and rural areas.

Applications can be submitted for:

- Non-repayable contributions from $250,000 up to $5 million per project for not-for-profit organizations.
- No interest, repayable contributions from $250,000 up to $5 million per project for incorporated businesses, including Indigenous businesses.

Explore our funding opportunities by clicking [here](https://www.mitacs.ca/en/programs) and choosing one of three funding streams.

**MITACS – leveraging partner funds to source funds for trainees**

While the MITACS program has been around a long time, it has undergone some significant changes to both programs and structure, and it is an underutilized source for funding trainee experiences. Consider leverage your existing partnered funding to apply for added funds for trainee management, travel and collaborative programs. Ongoing applications, simplified submission procedures, and high success rates!

- Eligible partners include companies (anywhere in the world!) and not-for-profits (Canada)
- Get funding for projects big or small (4 months to 4 years or longer)
- Funding includes both stipends and research expenses

Connect with MITACS specialist Ryan Caldwell, [rcaldwell@mitacs.ca](mailto:rcaldwell@mitacs.ca) located at McMaster Industry Liaison Office (MILO).


**Alton Ochsner Award Relating Smoking and Disease**

The Alton Ochsner Award recognizes outstanding scientific achievements that have provided pivotal insights into the fundamental biological and clinical mechanisms that relate tobacco consumption with disease. This scientific work may be clinical, fundamental, epidemiological, or prevention in scope. The prime criterion for award is its scientific context and impact on this major health threat. All nominations, whatever the category of scientific inquiry, must be supported by...
letters and copies of peer-reviewed scientific publications as detailed below.

One to three investigators will receive an award of $15,000.

Nominations should be made by a letter describing in detail, but concisely, the scientific work and major contributions of the investigator to the field. Self-nominations are excluded. The nomination packet must also include and be supported by:

1. Nominee’s CV (including active mailing address, office and cell telephone numbers, e-mail address, and bibliography);
2. At least 2 additional supporting letters from scientific peers from outside the candidate’s institution;
3. Reprints of at least 3 pertinent major scientific contributions.

Submissions should be made as PDF attachment(s) sent electronically to the Ochsner Clinic at AOSRA@ochsner.org. Any nominees not receiving the award will automatically be considered for an additional two years. Unsuccessful candidates must wait two years before being re-nominated, after those three years of consideration.

**Deadline:** March 31, 2019

For more information please contact Danelle D’Alvise at dalvise@mcmaster.ca.

**Host a Clinical Trials Intern**

Western University’s Clinical Trials Management post-degree diploma is now recruiting hosts and sites for summer practicums. If you are interested in more information, please connect with Katrina McIntosh, Katrina.mcintosh@uwo.ca, 519-661-2111 x85211, or check out further details at http://hostanintern.uwo.ca.

The Clinical Trials Management program is a one-year post-degree program that includes 9 clinical trials courses and a mandatory practicum. Enrollment is competitive and candidates must have an undergraduate Science or Health Science degree. In order to graduate from the program, students must complete a 400 hour practicum which is scheduled to run from May – August, 2019 (end dates vary based on hours/week at the site, which is flexible).

**MIRA 2019 Funding**

**TRAINEE FUNDING**

**MIRA Graduate Student Travel Awards**

**Deadlines to apply:** September 6
**Funding available:** Up to 10 awards of $500

Graduate students travelling to collect data or to present research at an academic conference are eligible for up to $500 in travel funding from MIRA. For more details, click here; Download the application form here.

**MIRA Postdoctoral Fellowships**

**Deadline to apply:** May 1
**Funding available:** Up to three awards of $50,000; requires supervisor match of at least $10,000 for benefits

Prospective post-doctoral Fellows are invited to submit a research plan that focuses on interdisciplinary, impact-driven approaches in the study of optimal aging through one or more of the following themes: 1) impact of exercise on mobility; 2) interrelationship between psychological function and social function; 3) causes and consequences of multimorbidity, frailty, and polypharmacy; 4) role of caregiving, equity, economics and transportation in optimal aging; 5) understanding the biological mechanisms of diseases of aging; 6) evaluating approaches to knowledge translation to improve optimal aging; and, 7) use of technology to promote optimal aging and aging in place. The applicant and principal supervisor are expected to involve at least two other researchers from two different McMaster Faculties (outside of the principal supervisor’s Faculty) as mentors in the development of an interdisciplinary research plan. For more information, click here; Download the application form here.
Labarge Graduate Scholarships in Mobility in Aging

Deadline to apply: May 15
Funding available: One award each of $15,000 (Master’s) and $18,000 (PhD)

Students beginning a new graduate degree are eligible to apply for the Labarge Graduate Scholarship. The student’s research focus must be related to aging and mobility, and requires both a MIRA supervisor and a mentor from a Faculty outside of the supervisor’s. For more information, click here.

AGE-WELL/MIRA Co-Funded Trainee Awards

Information Session: March 29, 9 – 10 a.m., MDCL 3504

Anticipated deadline: May 31

Available funding: Master’s level $15,000, PhD level $18,000, Postdoctoral $50,000

MIRA and AGE-WELL have partnered to co-fund awards for trainees who are working to drive innovation and create technologies and services that benefit older adults and caregivers. Projects must fit within AGE-WELL’s vision to harness and build upon the potential of emerging and advanced technologies in areas such as artificial intelligence (AI), e-health, information communication technologies (ICTS), and mobile technologies to stimulate technological, social, and policy innovation. Funding period is September 2019 - March 2020. To be eligible for this funding, McMaster applicants must notify MIRA research coordinator Audrey Patocs (patocsae@mcmaster.ca) of their intent to be considered for the award. More information.

RESEARCH GRANTS

Catalyst Grants: MIRA & Labarge Centre for Mobility in Aging

Deadline: April 30
Funding available: $40,000 over one year; six grants available (one per McMaster Faculty)

MIRA/Labarge Catalyst grants offer the opportunity to conduct collaborative and interdisciplinary research focused on mobility in aging, where mobility may include physiological, social, and financial mobility, as well as mobility within community or health systems. These grants are intended to stimulate new collaborations and allow researchers to collect preliminary data, conduct feasibility or pilot studies, or scaling of interventions. The ultimate goal of this funding is to support future proposals for full-scale studies. Each Faculty, through the Associate Dean (Research), is asked to nominate one proposal to be funded by MIRA. Submissions should include researchers from at least three different McMaster Faculties as meaningful contributors to the project. These grants require matching funds of at least $5000 (up to $2500 may be in-kind contributions) from alternate sources to support the project. For more details, click here; Download the application form here.

Canadian Longitudinal Study on Aging: Call for Proposals

2019 application deadlines: June 3, and September 23

Funding available: MIRA can support access fees ($3,000) for up to 10 CLSA data applications

MIRA members are eligible for support in accessing CLSA data, a national database tracking 50,000 Canadians aged 45 to 85 over a period of 20 years. Data access applications are accepted three times per year. Researchers should notify Audrey Patocs by emailing her at patocsae@mcmaster.ca prior to applying for CLSA data access to be considered for MIRA funding. MIRA funds will be allocated only to projects that do not have any other funding for this purpose. More information

MIRA/LCMA Matching Funding for External, Competitive Funding Calls
Deadline: Rolling

Funding available: Matching funds up to $100,000

In order to improve the positioning of McMaster’s researchers in external funding competitions, MIRA and the Labarge Centre for Mobility in Aging have allocated funding that may be used to match or leverage external funds. This process is intended to be used for requests related to externally funded, peer-reviewed grant competitions that require a matching component. For more details, click here.

Research Project Management Course at UofT

Good project management is vital to the success of major research projects. UofT has developed a course specifically tailored for the project management of research projects. The course has been adapted for research project management through the collaboration of an Advisory Group of faculty and staff, the School of Continuing Studies, staff from the Division of the Vice-President, Research & Innovation, and the instructor, Dr. Alison Paprica. Dr. Paprica (Assistant Professor [status] at the U of T Institute of Health Policy, Management & Evaluation), was previously the Director responsible for up to $60 million/year of government research funding and has also led numerous large-scale R&D projects in the private, public and not-for-profit sectors.

The course is designed for faculty researchers, staff scientists, post-doctoral fellows, research coordinators and those interested in a path to management and research leadership. This is the second year the course is being offered. Last year, given demand for the fall course, we mounted an additional section for the winter.

Information and registration can be found at 3382 Project Management for Research.

Invitation for feedback: Prioritizing Future Challenges for Canada

Canada’s three research granting agencies, the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, the Social Sciences and Humanities Research Council of Canada (CIHR, NSERC, SSHRC), and the Canada Foundation for Innovation, are seeking your expertise to help prioritize which future challenges identified through a recent horizon scan are considered most important for Canada.

Outcomes from this consultation may also be leveraged to support the priorities of the Canada Research Coordinating Committee (CRCC), notably to advance efforts in identifying key emerging research areas. Stakeholders from all four agencies are invited to participate in this consultation. Information on the CRCC’s priorities is available on the CRCC’s website. Building upon the success of SSHRC’s 2014 Imagining Canada’s Future initiative, the granting agencies partnered with Policy Horizons Canada, a federal centre of foresight expertise, to undertake a horizon scan as a first step in identifying future challenges for Canada over the next 10 to 15 years.

Policy Horizons Canada drew on sources from across digital media, academic studies, and foresight projects to identify and analyze change data for its global scan. They also conducted a literature review of over 600 early change indicators, and examined additional materials produced by Policy Horizons Canada, government departments and agencies, and other organizations around the world. These approaches were complemented by an online questionnaire engaging various key networks and foresight communities from more than 60 countries.

The scan has identified 16 future challenges with the potential to shape society in profound ways, and which are all multi-disciplinary and require broad collaboration to address. The granting agencies ask that you select one top challenge and explore its possible impacts through a brief survey. For the challenge you select, you will be asked a series of questions. You will have the option of repeating the exercise for a challenge you deem of next-most importance. The granting agencies are inviting input from a variety of individuals across the academic, private, public and not-for-profit sectors, in Canada and internationally. Beyond the 16 challenges identified in the horizon scan, you have the opportunity to identify additional challenges deemed critical to Canada’s future.

By taking part in their brief prioritization exercise, using the Futurescaper crowdsourcing tool, you will help to identify which challenges to consider for possible future programming and/or corporate activities. Once you have reviewed the 16 future challenges, the exercise will take you about 10 to 15 minutes to complete. To begin, please follow this link: FUTURE CHALLENGES PRIORITIZATION
Results of this foresight exercise will be available by spring 2019. Responses are anonymous, and results will be aggregated to ensure anonymity.

Associated Links:
- Imagining Canada’s Future initiative
- Policy Horizons Canada
- Canada Research Coordinating Committee
- Social Sciences and Humanities Research Council of Canada
- Natural Sciences and Engineering Research Council of Canada
- Canadian Institutes of Health Research
- Canada Foundation for Innovation

Compilation of GDPR Guidelines Now Available
The Office for Human Research Protections has developed a new resource for IRBs, researchers, and sponsors that are involved in human subjects research in Europe. Titled Compilation of European GDPR Guidelines, the document lists the data protection authorities of all European countries that fall under the new E.U. General Data Protection Directive (GDPR). For each country, the compilation also provides the links to any general GDPR guidances, as well as specific guidances on the topics of Research, Legal Basis, Consent, and International Data Transfer.
The new Compilation is available here:
https://www.hhs.gov/ohrp/international/index.html

<table>
<thead>
<tr>
<th>Health Research Grant Competitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programs administered by Health Research Services, unless otherwise indicated. Email: <a href="mailto:hsresadm@mcmaster.ca">hsresadm@mcmaster.ca</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Funding Opportunity (CIHR)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR – Operating Grant: CEEHRC (Epigenetics) 2019</td>
<td>March 26</td>
<td>April 9</td>
<td></td>
</tr>
<tr>
<td>CIHR – Operating Grant: New Investigator Grants in Child and Youth Health</td>
<td>April 8</td>
<td>April 22</td>
<td></td>
</tr>
<tr>
<td>CIHR – Team Grant: Transnational Cardiovascular Research Projects</td>
<td>April 15</td>
<td>April 29</td>
<td></td>
</tr>
<tr>
<td>CIHR – Team Grant: Indigenous Component of Healthy Life Trajectories (I-HeLTI)</td>
<td>April 17</td>
<td>May 1</td>
<td></td>
</tr>
<tr>
<td>CIHR – Operating Grant: Early Career investigator Grants in Maternal, Reproductive, Child &amp; Youth Health</td>
<td>April 2</td>
<td>April 30</td>
<td>May 14</td>
</tr>
<tr>
<td>CIHR – Operating Grant: 9th Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)</td>
<td>June 3</td>
<td>June 17</td>
<td></td>
</tr>
<tr>
<td>CIHR – Operating Grant: CIHR Summer Institute on Equitable AI for Public Health</td>
<td>June 4</td>
<td>June 18</td>
<td></td>
</tr>
<tr>
<td><strong>NEW</strong> CIHR – Team Grant: Canadian Cancer Society Cancer Survivorship</td>
<td>May 29</td>
<td>Aug 27</td>
<td>Sept 10</td>
</tr>
<tr>
<td><strong>NEW</strong> CIHR – Team Grant: Cannabis Research in Priority Areas</td>
<td>May 15</td>
<td>Sept 24</td>
<td>Oct 8</td>
</tr>
<tr>
<td>CIHR – Team Grant: Next Generation Networks for Neuroscience (NeuroNEX)</td>
<td>June 14</td>
<td>Nov 29</td>
<td>Dec 13</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Funding Opportunity (Non-CIHR)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill &amp; Melinda Gates Foundation: Grand Challenges Explorations</td>
<td>March 27</td>
<td>April 10</td>
<td></td>
</tr>
<tr>
<td>Simons Foundation Autism Research Initiative (SFARI): Summer 2019 Pilot Award</td>
<td>April 4</td>
<td>April 18</td>
<td></td>
</tr>
<tr>
<td>SickKids Foundation: New Investigator Grants</td>
<td>April 8</td>
<td>April 22</td>
<td></td>
</tr>
<tr>
<td>Program</td>
<td>Start Date</td>
<td>End Date</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Canadian Research Society: Next Generation of Scientists</td>
<td>April 12</td>
<td>April 26</td>
<td></td>
</tr>
<tr>
<td>2020 Killam Research Fellowships Competition</td>
<td>May 1</td>
<td>May 15</td>
<td></td>
</tr>
<tr>
<td>Active &amp; Assisted Living Programme: Sustainable Smart Solutions for Ageing Well Call for Proposals</td>
<td>May 10</td>
<td>May 24</td>
<td></td>
</tr>
<tr>
<td>Child Health Foundation: Innovative Small Grants Program</td>
<td>May 17</td>
<td>May 31</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> Arthritis Society: Stars Career Development Award</td>
<td>May 22</td>
<td>June 12</td>
<td></td>
</tr>
<tr>
<td>Weston Brain Institute Rapid Response Parkinson’s &amp; Related Diseases</td>
<td>May 15</td>
<td>July 2</td>
<td></td>
</tr>
<tr>
<td>Weston Brain Institute Transformational Research Parkinson’s &amp; Related Diseases</td>
<td>May 15</td>
<td>July 2</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> The Michael J. Fox Foundation Grants: Therapeutic Pipeline Program</td>
<td>April 19</td>
<td>July 5</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> The Michael J. Fox Foundation Grants: Assay Development and Validation for Quantifying Oligomeric Alpha-Synuclein</td>
<td>April 19</td>
<td>July 5</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> The Michael J. Fox Foundation Grants: Biology of Astrocytes in Parkinson’s Disease</td>
<td>April 19</td>
<td>July 5</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> The Michael J. Fox Foundation Grants: Imaging Biomarkers to Track Disease Progression and Therapeutic Efficacy</td>
<td>April 19</td>
<td>July 5</td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s Drug Discovery Foundation (ADDF) and the Harrington Discovery Institute: ADDF-Harrington Scholar Program</td>
<td>April 12</td>
<td>July 5</td>
<td></td>
</tr>
<tr>
<td>Weston Brain Institute Rapid Response Alzheimer’s &amp; Related Diseases</td>
<td>April 1</td>
<td>July 16</td>
<td></td>
</tr>
<tr>
<td>Weston Brain Institute Transformational Research Alzheimer’s &amp; Related Diseases</td>
<td>April 1</td>
<td>July 16</td>
<td></td>
</tr>
<tr>
<td>Ontario Genomics: Genomics in Society Interdisciplinary Research Teams Program (GISIRT)</td>
<td>May 27</td>
<td>Aug 9</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> Arthritis Society: Strategic Operating Grants</td>
<td>April 15</td>
<td>Aug 9</td>
<td></td>
</tr>
<tr>
<td>Canadian Cancer Society: Impact Grants</td>
<td>April 17</td>
<td>Aug 27</td>
<td></td>
</tr>
<tr>
<td>Canadian Cancer Society: Travel Awards</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canadian Cancer Society: Junior Investigator Grant Panel Travel Award</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SickKids Foundation: Community Conference Grants</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer Research Society: Translational Research Partnership Program</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HHS: Clinical Health Professional Travel Awards</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Ontario HIV Treatment Network (OHTN), Endgame Funding Program: Community-Based Research and Evaluation (CBR&amp;E) Awards</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ontario Brain Institute (OBI): Event Funding Program</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crohn’s &amp; Colitis Foundation: IBD Ventures</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ontario Genomics: Genomic Applications Partnership Program (GAPP)</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weston Brain Institute Postdoctoral Scholars at Oxford</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weston Brain Institute International Fellowships: Canada</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> Alzheimer’s Drug Discovery Foundation: Prevention Beyond the Pipeline</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding Opportunity (DoD)</td>
<td>LOI Deadline</td>
<td>Internal HRS Deadline</td>
<td>Sponsor Deadline</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Alzheimer’s Drug Discovery Foundation: Drug Discovery Program</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s Drug Discovery Foundation: Neuroimaging &amp; CSF Biomarker Development Program</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McMaster University, McMaster Institute for Research on Aging (MIRA), Canadian Longitudinal Study on Aging (CLSA): Call for Proposals</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McMaster University, McMaster Institute for Research on Aging (MIRA), Labarge Centre for Mobility in Aging (LCMA): Matching Funds for Research Opportunities</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MITACS Globalink Research Award</td>
<td>Ongoing MILO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MITACS Accelerate Fellowship</td>
<td>Ongoing MILO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weston Brain Institute: Big Ideas</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weston Brain Institute: Early Phase Clinical Trials: Canada</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCE Voucher for Innovation and Productivity II (VIP II) Program</td>
<td>Ongoing MILO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MITACS Accelerate Program</td>
<td>Ongoing MILO</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(eBRAP account required – must be validated by McMaster prior to any submission)

Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP): Discovery Award
March 28
March 28
April 11

Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCRP): Exploration Hypothesis Development Award
April 18
April 25
May 9

Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCRP): Idea Development Award
April 18
April 25
May 9

Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCRP): Clinical Translational Research Award
April 18
April 25
May 9

Department of Defense (DoD) Military Burn Research Program (MBRP): Idea Development Award
April 17
June 26
July 10

Department of Defense (DoD) Military Burn Research Program (MBRP): Clinical Translational Research Award
April 17
June 26
July 10

Department of Defense (DoD) Amyotrophic Lateral Sclerosis Research Program (ALS RP): Therapeutic Development Award
March 22
July 11
July 25

Department of Defense (DoD) Amyotrophic Lateral Sclerosis Research Program (ALS RP): Therapeutic Idea Award
March 22
July 11
July 25

Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Pilot Award
April 23
July 10
July 24

Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Investigator-Initiated Research Award
April 23
July 10
July 24

Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Ovarian Cancer Academy Award - Early-Career Investigator
April 30
July 17
July 31

Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Ovarian Cancer Academy Dean and Assistant Dean (Leadership) Award
April 30
July 17
July 31

Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Clinical Development Award
April 30
July 17
July 31
**CIHR – Operating Grant: CEEHRC (Epigenetics) 2019**

This funding opportunity is expected to:

- Promote the continued coordination and integration of epigenetic and epigenomic research across Canada and internationally
- Promote the continued coordination and integration of knowledge translation activities across the CEEHRC funded components

**Funding Details:**

- $250,000 per year is available for four years to support the activities of the research consortia.
- $80,000 is available in year 1 of the grant, specifically for the planning, organization and hosting of the 2019 International Human Epigenome Consortium (IHEC) meeting.

**Additional Details**

**Internal HRS Deadline: March 26, 2019**
**Sponsor Deadline: April 9, 2019**

---

**CIHR – Operating Grant: New Investigator Grants in Child and Youth Health**

The SickKids Foundation–CIHR-IHDCYH New Investigator Research Grants in Child and Youth Health in Child and Youth Health program seeks to strengthen Canada’s capacity and knowledge to respond to children’s health challenges and needs. The grants are jointly sponsored by SickKids Foundation and the CIHR Institute of Human Development, Child and Youth Health (IHDCYH). New investigators (also referred to by CIHR as early career investigators) may obtain up to three years of support for research in biomedical, clinical, health systems and services, population and public health sectors that has the potential for significant impact on children’s health outcomes.

**Research Areas**

This funding opportunity will support projects relevant to both SickKids Foundation’s mission and IHDCYH’s mandate: SickKids Foundation’s mission is to improve the lives of children and their families in Canada and around the world. For more information, please consult the SickKids Foundation website.

**IHDCYH’s mandate** is to support research that ensures the best start in life for all Canadians and the achievement of their potential for optimal growth and development. This broad mandate covers defined time periods and a wide range of issues pertaining to human development: pre-conception, fertilization, embryonic and fetal development, the health of the mother and father, and the health and development of infants, children and youth (up to 25 years of age).

The aim of the SickKids Foundation–CIHR-IHDCYH New Investigator Research Grants in Child and Youth Health program is to provide important early career development support to child health researchers and enhance their ability to compete for future research grants.

**Funding Details:** The total amount available for this funding opportunity is $1,800,000, enough to fund approximately six (6) grants. The maximum amount for a single grant is $100,000 per annum for up to three (3) years, for a total of $300,000 per grant.

- Of this $1,800,000:
  - $300,000 is available to fund applications relevant to IHDCY’s mandate;
  - $1,500,000 is available to fund applications relevant to the mission of SickKids Foundation.

**Additional Details**

**Internal HRS Deadline: April 8, 2019**
**Sponsor Deadline: April 22, 2019**

---

**CIHR – Team Grant: Transnational Cardiovascular Research Projects**

The ERA-CVD JTC2019: Transnational Cardiovascular Research Projects driven by Early Career Scientists is expected to:

- foster transnational cooperation of European countries and beyond, and to coordinate research efforts and funding programs of the ERA-CVD partner countries with Canada
- promote co-operation and interchange between Early Career Scientists and thus enable international collaboration and new consortia establishment in cardiovascular research,
- enable capacity building and empowering of Early Career Scientists by providing opportunity to independently develop and perform highly innovative research projects,
- add value in funding the collaboration over individual projects by sharing of resources (e.g., models, databases, diagnosis etc.), harmonization of data, sharing of specific know-how and/or innovative technologies, etc.

**Funding Details:** CIHR-ICRH is partnering with other ERA-CVD partners to provide approximately EUR 10 million for JTC2019. The total amount available for Canadian applications is CAD 600,000, which is enough to fund approximately two (2) grants. This amount
may increase if additional funding partners participate. The maximum amount available per grant to Canadian participants in transnational consortia is CAD 100,000 per year for up to three (3) years for a total of CAD 300,000, per grant.

Additional Details
Internal HRS Deadline: April 15, 2019
Sponsor Deadline: April 29, 2019

CIHR – Team Grant: Indigenous Component of Healthy Life Trajectories (I-HeLTI)

Non-communicable diseases (NCDs) are responsible for more than 60% of deaths globally, and 80% of these NCD-associated deaths occur in countries that have experienced rapid changes in population demographics (2–4 generations) and environments, including urbanisation, lifestyle changes and changes in diet. To address these issues, CIHR developed the Healthy Life Trajectories Initiative (HeLTI), which follows a Developmental Origins of Health and Disease (DOHaD) approach, by exploring how the interaction of environmental factors with genes prior to and during conception, pregnancy, infancy and early childhood impacts an individual’s health and the development of NCDs in later life. CIHR is currently funding an International component of HeLTI, through a partnership among research teams, the World Health Organization, and funding agencies based in Canada, South Africa, China and India. These countries have experienced rapid changes in population demographics and environments, and have a high incidence of NCDs.

NCDs, including diabetes, cardiovascular diseases, and respiratory diseases, are also a priority issue for Indigenous Peoples (First Nations, Inuit and Métis) in Canada. CIHR has therefore launched the Indigenous component of HeLTI (I-HeLTI) to address similar issues faced by and specific to Indigenous Peoples in Canada. I-HeLTI will take a DOHaD approach, supporting the development, implementation, testing and evaluation of Indigenous-focused early interventions (preconception, pregnancy, infancy and early childhood) designed to improve health outcomes in later life for Indigenous boys, girls, women, men, gender-diverse and Two-Spirit individuals in Canada.

Development Grants have been funded to bring interested Indigenous communities together with self-identified relevant organizations to build community participation in I-HeLTI and to establish needed expertise to support Indigenous-driven health research. Recipients of these Development Grants participated in a Strengthening Workshop that addressed community readiness, priorities, research capacity, data capacity considerations, sex and gender considerations and governance, as well as building relationships with researchers.

This funding opportunity will fund four (4) I-HeLTI research teams that will build the infrastructure and capacity that is needed to conduct an Indigenous-driven I-HeLTI DOHaD Intervention Cohort Research Study. This funding opportunity is not restricted only to those who received a development grant. I-HeLTI will operate according to Indigenous self-governance and self-determination, recognizing the need to respect how Indigenous Peoples must be involved in health research.

A subsequent funding opportunity for one (1) Indigenous-driven I-HeLTI DOHaD Intervention Cohort will coincide with the renewal date of the team grant funding. It is expected that the four funded teams will collaborate to respond to the intervention cohort funding opportunity and establish one Indigenous-driven I-HeLTI DOHaD Intervention Cohort. As such, the funded research teams will collaborate to develop the partnerships, and leverage the necessary expertise and resources to establish an Indigenous-driven I-HeLTI DOHaD Intervention Cohort. This will include working together to define roles and responsibilities around research governance, and research data management.

As part of this, the funded teams will be provided with the common dataset variables that are being collected by the International component of HeLTI in order to determine which of the variables are culturally appropriate and feasible for use in I-HeLTI. They will also evaluate the data management processes established by the International cohorts for utility in I-HeLTI. Funded teams will then develop data management processes including how data and biosamples will be collected, documented and stored during the lifecycle of the project in a manner that will optimize the opportunity to share, link, integrate and harmonize data, if and when Indigenous Peoples make the decision to do so.

This funding opportunity is to support research over two (2) fiscal years (2019-20 to 2020-21) with the possibility of renewals for a total of eight years of support up to 2026-27. In order to enable the development of infrastructure and capacity by each of the teams in preparation for joining the Indigenous-driven I-HeLTI DOHaD Intervention Cohort, in the first two years (fiscal years 2019-20 to 2020-21), the teams will receive infrastructure funding to support capacity building and infrastructure in addition to baseline funding. Upon renewal, the baseline funding will then continue for the remaining term (up to fiscal year 2026-27) of the team grants to provide local funding to each of the teams to support their roles within the overall I-HeLTI DOHaD Intervention Cohort collaboration.

I-HeLTI team grants will sustain the I-HeLTI investment through long-term Indigenous community engagement and institutional commitments.
Research Areas
This funding opportunity will support teams to build infrastructure and capacity along the continuum of care and prevention from preconception to pregnancy, infancy and early childhood, with a life trajectory perspective relevant to the following research areas:

- A DOHaD / life trajectory approach;
- A focus on the prevention of NCDs; and
- An intervention cohort design.

Interventions must target evidence-based, modifiable risk factors for one or more NCDs. Interventions can be natural experiments (e.g., policy, programs, or other interventions not under the control of a researcher), or newly implemented or adapted interventions delivered by the researcher team or others.

For this I-HeLTI funding opportunity, the objectives will need to be addressed within an Indigenous health research context. That is, the approach to the funding opportunity objectives will need to be conducted by, grounded in, or engaged with First Nations, Inuit or Métis communities, societies or individuals and their wisdom, cultures, experiences or knowledge systems, as expressed in their dynamic forms, past and present.

Funding Details: The total amount available for this funding opportunity is $4,050,000, enough to fund four (4) grants over two (2) years. The maximum amount per grant for this funding opportunity is $1,012,500, with the possibility of renewals.

- Of the $1,012,500 per grant:
  - $325,000 is available for the team activities (baseline funding – $125,000 in year 1 and $200,000 in year 2)
  - $687,500 is available per grant to support infrastructure, capacity building and partnerships. ($325,000 in year 1 and $362,500 in year 2).

- There is the possibility of renewals for an additional total amount of $4,800,000. An additional $1,200,000 per grant ($200,000 per year for up to six [6] years) will be available for renewals if successful in joining the one (1) funded Indigenous-driven I-HeLTI DOHaD Intervention Cohort.

Additional Details
Internal HRS Deadline: April 17, 2019
Sponsor Deadline: May 1, 2019

Operating Grant: Early Career investigator Grants in Maternal, Reproductive, Child & Youth Health
This funding opportunity is a collaboration between three CIHR institutes with a goal to build research capacity in maternal, reproductive, child and youth health by funding operating grants to early career investigators.

The program will fund research across the four CIHR research themes (biomedical, clinical, health services, and social, cultural, environmental, and population health) that has the potential to have a significant impact on maternal, reproductive, child and youth health outcomes according to the mandates of the participating CIHR institutes. Ultimately, the program aims to strengthen Canada’s capacity and knowledge to respond to challenges and needs by providing important early career development support to researchers in these fields.

This funding opportunity does not require applicants to participate in a mentoring program or have a formal mentorship plan; however, having a system of research support/advice is something that applicants should think carefully about. CIHR has a Training and Mentoring Learning Module. While the module was developed for applicants to the Foundation Grant program, there is a subsection on “Best Practices” that provides information on what makes an effective mentor and mentoring program and is generally applicable.

Research Areas
All applications in the area of maternal, reproductive, child and youth health research as per IHDCYH’s mandate will be eligible for support.

In addition, funding is available to support projects that are determined to be relevant to the following specific research areas:

- ECIs in MRCYH – Infection and Immunity: Maternal, reproductive, child and/or youth health research relevant to the Institute of Infection and Immunity’s mandate.
- ECIs in MRCYH - Neurosciences, Mental Health and Addiction: Maternal, reproductive, child and/or youth health research relevant to the Institute of Neurosciences, Mental Health and Addiction’s mandate.

In keeping with the CIHR Sex, Gender and Health Research policy, all proposals are expected to consider how sex and/or gender might shape the research described. Applicants are encouraged to visit the CIHR sex- and gender-based analysis resource page for more information on key considerations for the appropriate integration of sex and gender in their proposal.
Funding Details: The total amount available from CIHR for this funding opportunity is $945,000, enough to fund up to 9 grants. The maximum amount per grant from CIHR is $35,000 per year for up to 3 years, for a total of $105,000.

- Of the $945,000:
  - $210,000 is available to fund applications in the research area relevant to III (2 grants).
  - $105,000 is available to fund applications in the research area relevant to INMHA (1 grant).
  - $630,000 is available to fund applications in a general pool, which will be comprised, of all remaining fundable applications in the competition. (6 grants).
- Applicants must secure partner contribution from non-federal sources to match the CIHR contribution at a minimum of 1:1 ratio by the successful applicant’s host institution and/or other partner(s), which may include but are not limited to foundations, health charities, community groups, industry and private sector.
  - Matching funds must be 100% cash contributions; cash equivalent matching contributions are not eligible.
  - Matching funds must be committed by the application deadline date; details must be provided in the Partnership Details form (see How to Apply section).
  - Start-up funds provided to an applicant by their host institution are eligible as matching funds if some, or all, of those funds can be committed to the project. Any portion of start-up funding already committed to another research project is not eligible. The details must be provided in a letter of support (see How to Apply section).

Additional Details
Registration Deadline: April 2, 2019
Internal HRS Deadline: April 30, 2019
Sponsor Deadline: May 14, 2019

CIHR – Operating Grant: 9th Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)
The funding opportunity is expected to:
Contribute to the urgent need to curb the burden associated with the most prioritized infections in different geographical settings through international collaborations, combining complementary and synergistic research strengths and a One Health perspective.

This topic area is also suitable to reinforce collaborations involving industry and social sciences. Regional LMIC-led collaborations are welcomed. The results of the funded projects should contribute to improved understanding, monitoring and detection of AMR where efforts to curb AMR will have a global impact.

For more information, please consult the JPIAMR website.

This funding opportunity will support projects relevant to the following research areas:
- Establish the validity of new or improved diagnostic tools, technologies and methods.
- Evaluate how new or improved diagnostics can promote more prudent use of antibiotics (e.g., narrow spectrum antibiotics) in human and veterinary use.
- Rapid diagnostics (essential for optimal antimicrobial selection) and point-of-care techniques, to improve personalized or individual therapies.
- Development of new, or more efficient use and accessibility of already existing, tools, technologies and/or methods to detect AMR in multiple reservoirs, for example human, animal and environmental samples, for example:
  - Improvement and standardisation of bioinformatics pipelines, quality control, and/or modelling and analysis tools for WGS data and metadata.
  - Methods and tools for defining baseline data with regards to the natural variability of resistance genes, mobile genetic elements and/or mobilization/transfer frequencies in different types of environments and/or expanding quantitative microbial risk assessment to encompass also, e.g., ecology and evolutionary aspects of AMR.
  - Implementation strategies and/or improvement or further development of existing tools that distinguish between viral, susceptible bacterial and antimicrobial-resistant bacterial infections.

Projects are encouraged to consider the global use of the tools, technologies and methods, including use in LMIC settings (e.g. lack of laboratory facilities, affordable diagnostic tests, unreliable or unavailable electricity supplies or points-of-care-tests).

- Funding Details: The total amount available for this funding opportunity is CAD 1.8 million, enough to fund approximately 4 grants. This amount may increase if additional funding partners participate. The maximum amount per grant is based upon the nature of Canadian participation on the funded application as follows:
  - Canadian investigator–led Consortium (Coordinator): The maximum per grant is up to CAD 175,000 per year for up to 3 years, for a total of CAD 525,000 per grant.
Canadian investigator participation (Partner): The maximum per grant is up to CAD 125,000 per year for up to 3 years, for a total of CAD 375,000.

- Approved grants may receive an across-the-board cut to the budget, if necessary, to maximize the number of funded opportunities.

**Additional Details**

**Internal HRS Deadline:** June 3, 2019  
**Sponsor Deadline:** June 17, 2019

**CIHR – Operating Grant: CIHR Summer Institute on Equitable AI for Public Health**

The main objectives of the CIHR Summer Institute on Equitable AI for Public Health funding opportunity, led by the host institution(s) are to:

- Equip doctoral and post-doctoral trainees and early career researchers from primarily public health and, secondarily, computational sciences backgrounds with the technical skills to use AI approaches and methods to tackle key public health challenges;
- Prepare participants to address the equity implications of different AI approaches, including identifying strategies to prevent and mitigate potential inequities that could result when using AI approaches in public health research and practice, and opportunities for leveraging AI to advance health equity;
- Facilitate a high-quality, interdisciplinary learning environment that offers participants from across Canada the opportunity to interact with others from a diverse range of backgrounds and disciplines within public health and computational sciences, as well as Canadian and international leaders and implementers working in AI and public health; and
- Catalyze the development of open-access training content and materials focused on using AI approaches in public health research that can be adapted and integrated into curricula for trainees at schools of public health and related disciplines, and among staff at public health agencies across Canada.

- **Funding Details:** $525,000 over five (5) years, enough to fund one grant. This amount may increase if additional funding partners participate.

**Additional Details**

**Internal HRS Deadline:** June 4, 2019  
**Sponsor Deadline:** June 18, 2019

**CIHR – Team Grant: Canadian Cancer Society Cancer Survivorship**

The goal of the CCS/CIHR Cancer Survivorship Team Grant program is to improve the health outcomes for cancer survivors of all ages (pediatric, adolescent, young adult and adult) from the time of their cancer diagnosis until the time of their death or entry into palliative care. This program is not intended to focus on improving end-of-life care.

The intent of this funding opportunity is to support new intervention research designed to mitigate the challenges experienced along the survivorship journey, as well as the evaluation and validation of existing interventions to assess their potential for implementation as best practices.

The program goal will be achieved through the support of a network of multidisciplinary teams, each led by a nominated Principal Investigator and at least 2 co-Principal and/or co- Applicants, one of whom must be within their first five years as an independent researcher, drawn from at least 3 different regions of Canada (Atlantic Provinces, Central Canada, Prairie Provinces, West Coast, Northern Territories).

Collectively, successful teams will be expected to generate relevant new knowledge and to develop and evaluate practical strategies and interventions, in real world settings, that will prevent or diminish the adverse sequelae of a cancer diagnosis and have a positive impact on subsequent health outcomes for cancer survivors.

Collectively, successful teams will be expected to generate relevant new knowledge and to develop and evaluate practical strategies and interventions, in real world settings, that will prevent or diminish the adverse sequelae of a cancer diagnosis and have a positive impact on subsequent health outcomes for cancer survivors.

In addition, each team will be required to develop a well-designed plan for integration within their team of:

- Implementation science approaches aimed at facilitating the development of strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and/or sustainability of evidence-based interventions. Strategies designed to integrate evidence-based interventions into specific settings are strongly encouraged.
• A research model that embodies the values of community-based participatory research (CBPR), in which survivors and their family/friend caregivers are engaged throughout the entire research process from the development of the initial research questions to the dissemination and application of research findings.

• Each team should include (have a balance of) investigators across the continuum of a research career (early, mid and late), (Assistant, Associate, Full) professorship, and diversity, with a built-in plan for mentorship and sustainability.

The program goal will be achieved through regular networking events/activities designed to support and augment individual teams’ capacities to catalyze survivor/caregiver engagement and knowledge mobilization.

**Funding Details:** Teams may request up to $500,000 per year for a maximum of $2,500,000 over a five-year period. Grants will be non-renewable. As the total budget for this competition is $10 million, it is anticipated that at least 4 teams will be funded in this competition. The engagement of additional partners may increase this number.

Funding will be provided to support the direct costs of research, including supplies, salaries, and equipment associated with the proposed work. Equipment requests cannot exceed 10% of the requested budget. Indirect costs are not eligible. *Note that funds should be set aside in the budget to facilitate travel of teams for networking purposes annually.

**Additional Details**

**LOI Deadline:** May 29, 2019  
**Internal HRS Deadline:** August 27, 2019  
**Sponsor Deadline:** September 10, 2019

### CIHR – Team Grant: Cannabis Research in Priority Areas

On October 17, 2018, the Cannabis Act came into force in Canada, legalizing non-medical cannabis products including fresh and dried cannabis, and cannabis oils. Other products, such as edible products and concentrates, are expected to be legal for sale in Fall 2019. There remain many unknowns about the use of cannabis, its health and safety effects and the behavioural, social, cultural, ethical and economic implications of legalization both nationally and across jurisdictions. A number of reports have highlighted the need for enhanced research evidence to inform policy, therapeutic practice, harm reduction, and prevention efforts.

In December 2017, CIHR invested $1.4 million to support 14 projects to catalyze future research related to the health impacts of cannabis legalization. That catalyst grant funding opportunity had a specific focus on population health intervention research related to the legalization and regulation of non-medical cannabis in Canada. Further, in July 2018, CIHR and partners invested $3 million to support an additional 24 projects designed to address urgent priority areas identified through a research priorities workshop held in September 2017. Identified research areas included both the potential therapeutic benefit for specific indications and the potential risks/harms of cannabis use in different populations. However, there still remain many unknowns about the health and safety effects of cannabis, as well as the behavioural, social, ethical and economic implications of legalization.

To address these issues, CIHR and partner agencies have developed an [Integrated Cannabis Research Strategy (ICRS)](https://www.cihr-irsc.gc.ca/e/52603.html). The overarching vision of ICRS is to provide a well-coordinated series of activities to position Canada as a leader in developing the research capacity and amassing the research evidence needed on the effects of cannabis. This includes validating the potential therapeutic benefits of cannabis, as well as understanding risks and harms, and supporting policy and regulatory models for studying cannabis use (including development of common data standards). This Team Grant funding opportunity represents the first targeted funding opportunity launched under ICRS, with additional opportunities planned in the coming years.

The purpose of the current Team Grant is to explore in more detail the potential therapeutic benefits and harms associated with cannabis use in a number of targeted areas identified through previous consultations. In particular, these Team Grants will address stakeholder priorities by supporting specific defined priority areas in targeted pools, to strengthen the evidence base and to build cannabis-related research capacity.

To ensure that applications address the ethical, environmental, economic, legal, social and cultural aspects associated with cannabis research, applications should demonstrate relevant interdisciplinary expertise encompassing research domains from natural sciences and engineering, health sciences, and social sciences and humanities, as appropriate, in their applications. Applicants must propose a knowledge translation plan and demonstrate how they will incorporate open science practices in their research program.

Applicants must integrate sex as a biological variable and gender as a social determinant of health, as appropriate, into their research to promote rigorous science that has the potential to expand our understanding of health determinants for all people. As such, applicants are required to indicate how they will account for sex (biological factor) and gender (socio-cultural factor) in the research design, methods, analysis and interpretation, and dissemination of findings. For more information and resources, please see the Sex, Gender and Health Research page on the CIHR website.
The Bill & Melinda Gates Foundation is inviting grant proposals for the following Grand Challenges initiatives:

**Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative**

In the United States, the US National Science Foundation (NSF) has developed the Next Generation Networks for Neuroscience (NeuroNex). The objective of the NeuroNex program is to establish distributed, international research networks that build on existing global investments in neurotechnologies to address overarching questions in neuroscience. The creation of such global research networks of excellence will foster international cooperation by seeding close interactions between a wide array of organizations across the world, as well as creating links and articulating alliances between multiple recently launched international brain projects. Canadian researchers are well placed to provide a leadership role within NeuroNex networks.

**Funding Details:** The maximum amount per grant is $250,000 per year for up to 5 years for a total of $1,250,000 per grant.

**Additional Details**

**Pre-Proposal Deadline:** June 14, 2019
**Internal HRS Deadline:** November 29, 2019
**Sponsor Deadline:** December 13, 2019

**Bill & Melinda Gates Foundation: Grand Challenges Explorations**

The Bill & Melinda Gates Foundation is inviting grant proposals for the following Grand Challenges initiatives:

**Funding Details:** The total amount available for this funding opportunity is $16.5 million, enough to fund approximately 11 grants. This amount may increase if additional funding partners participate. The maximum amount per grant is $300,000 per year for up to 5 years, for a total of $1.5 million per grant.

Of this $16.5 million:

- $1.5 million is available to fund an application relevant to the Cancer Pool (sponsored by the Canadian Cancer Society, ICR, and INMHA).
- $1.5 million is available to fund an application relevant to the Cardio-Respiratory/Sleep Pool (sponsored by ICRH).
- $1.5 million is available to fund an application relevant to the Neurodevelopment Pool (sponsored by IHDCYH).
- $1.5 million is available to fund an application relevant to the Indigenous Peoples' Health Pool (sponsored by IIPH and INMHA).
- $1.5 million is available to fund an application relevant to the IMHA Pain Pool (sponsored by IMHA).
- $1.5 million is available to fund an application relevant to the Arthritis Pain Pool (sponsored by the Arthritis Society and INMHA).
- $4.5 million is available to fund applications relevant to the Mental Health Pool (sponsored by INMHA and MHCC).
- $1.5 million is available to fund an application relevant to the MS Pool (sponsored by the MS Society of Canada and INMHA).
- $1.5 million is available to fund an application in any of the Research Areas pools in overall rank order of application (sponsored by INMHA).
- If any additional unrestricted funds are secured, they will be applied to fund applications in any of the indicated Research Areas pools in overall rank order of application.

**Additional Details**

**LOI Deadline:** May 15, 2019
**Internal HRS Deadline:** September 24, 2019
**Sponsor Deadline:** October 8, 2019

**CIHR – Team Grant: Next Generation Networks for Neuroscience (NeuroNEX)**

CIHR and FRQ have decided to support Canadian investigators on a large-scale, interdisciplinary, international brain research initiative. Understanding how behavior emerges from the dynamic patterns of electrical and chemical activity of brain circuits is universally recognized as one of the great, unsolved mysteries of science. Advances in recent decades have elucidated how individual elements of the nervous system and brain relate to specific behaviors and cognitive processes. However, there remains much to discover to attain a comprehensive understanding of how the healthy brain functions, specifically, the general principles underlying how cognition and behavior relate to the brain’s structural organization and dynamic activities, how the brain interacts with its environment, and how brains maintain their functionality over time.

As part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative in the United States, the US National Science Foundation (NSF) has developed the Next Generation Networks for Neuroscience (NeuroNex). The objective of the NeuroNex program is the establishment of distributed, international research networks that build on existing global investments in neurotechnologies to address overarching questions in neuroscience. The creation of such global research networks of excellence will foster international cooperation by seeding close interactions between a wide array of organizations across the world, as well as creating links and articulating alliances between multiple recently launched international brain projects. Canadian researchers are well placed to provide a leadership role within NeuroNex networks.

The goal of the NeuroNex Technology-enabled, Team-based Neuroscience solicitation is to support collaborative networks comprised of international teams of disciplinarily-diverse researchers working on a common foundational question in neuroscience. Each network will be organized around a central theme identified by the participants. Individual networks will be composed of 2 to 4 interdisciplinary research groups (IRGs), each consisting of about 3 to 6 investigators. Each IRG will have a defined intellectual role that fits within the overall research goal of the network. It is envisaged that the composition of each IRG may cut across organizations and countries, as appropriate. Through this funding opportunity, CIHR and FRQ will support Canadian investigators on NeuroNex IRGs.

**Funding Details:** The maximum amount per grant is $250,000 per year for up to 5 years for a total of $1,250,000 per grant.


Increasing Demand for Vaccination Services: [https://gcgh.grandchallenges.org/challenge/increasing-demand-vaccination-services-round-23](https://gcgh.grandchallenges.org/challenge/increasing-demand-vaccination-services-round-23)

**Funding Details**: Initial grants are awarded $100,000. Successful projects have the opportunity to receive follow-on funding; a maximum $1 million.

**Additional Details**

Internal HRS Deadline: March 27, 2019
Sponsor Deadline: April 10, 2019

**Simons Foundation Autism Research Initiative (SFARI): Summer 2019 Pilot Award**

The goal of the Pilot Award is to provide early support for exploratory ideas, particularly those with novel hypotheses. Appropriate projects for this mechanism include those considered higher risk but with the potential for transformative results. To get a better understanding of SFARI’s different RFAs and whether the Pilot Award may be the best mechanism to support your project, please read our blog post “SFARI RFA reboot: Why, what and how?”

In particular, we encourage applications that propose research to link genetic or other ASD risk factors to molecular, cellular, circuit or behavioral mechanisms of ASD. Please read more about SFARI’s scientific perspectives [here](https://sfarionline.org/scientificperspectives). We also strongly advise applicants to familiarize themselves with the [current projects](https://sfarionline.org/currentprojects) and other [resources](https://sfarionline.org/resources) that SFARI supports and to think about how their proposals might complement existing efforts.

**Funding Details**: A maximum $300,000 over a maximum 2 years.

**Additional Details**

Internal HRS Deadline: April 4, 2019
Sponsor Deadline: April 18, 2019

**SickKids Foundation: New Investigator Grants**

The objective is to provide early career development support to new child health investigators who successfully lead, participate in, and translate outstanding child health research that responds to children’s health challenges and needs. Research in the biomedical, clinical, health systems and services, population and public health sectors, are eligible.

The Principal Investigator (PI) must hold a doctoral degree (Ph.D.) or equivalent medical/health care degree, and have had formal research training. The PI must be within five years of their first academic appointment, and has not been awarded combined Operating Grant funding of $500,000 or more.

**Funding Details**: A maximum $100,000 per year for a maximum 3 years.

**Additional Details**

Internal HRS Deadline: April 8, 2019
Sponsor Deadline: April 22, 2019

**Canadian Research Society: Next Generation of Scientists**

Scholarships for the Next Generation of Scientists is a Cancer Research Society funding program with the goal of supporting the future generation of Canadian researchers. The award consists of two part covering a period of three years, with no possibility for renewal.

The one-year postdoctoral salary award are for a candidate finishing his/her fellowship. The candidate must have completed at least two (2) years of postdoctoral training when he/she will accept the salary award on September 1st.

There is a possibility of extending Part 1 of this award for a maximum period of six months.

The operating grant is awarded once the candidate has obtained a faculty position at a recognized Canadian institution. This grant is for a maximum of two years.

**IMPORTANT**: Applying for only one part of the award is prohibited.

**Funding Details**: Part 1: 1 year - $50,000. Part 2: 2 years $120,000.
**2020 Killam Research Fellowships Competition**

The Killam Research Fellowships are release time awards that provide support to scholars of exceptional ability who are engaged in research projects of broad significance and widespread interest within the disciplines of the humanities, social sciences, natural sciences, health sciences, engineering, or studies linking any of these disciplines.

**Funding Details:** Fellowships are valued at $70,000 per year for 2 years.

---

**Active & Assisted Living Programme: Sustainable Smart Solutions for Ageing Well Call for Proposals**

AAL Call 2019 is part of the Active & Assisted Living Programme (AAL Programme) that was approved in May 2014 by the European Parliament and the Council of the European Union. As part of the work programme, the AAL Programme intends to launch a new Call for Proposals in February 2019: “Sustainable Smart Solutions for Ageing well”.

The aim of the call is to support innovative, transnational and multi-disciplinary collaborative projects. Call 2019 is characterised by the following approach:

- The AAL Call 2019 is open to developing ICT-based solutions targeting any application area(s) within the AAL domain. The solutions need to be embedded in the strategies of the participating end-user organisations, service providers and business partners.
- The AAL Call 2019 allows for more flexibility regarding the scope, size and duration of the proposed projects (including small collaborative projects).

The AAL domains include solutions for Active Living, such as in work & training, for vitality & abilities, in leisure & culture, for information & communication, as well as for Assisted Living, such as in health & care, living & building, mobility & transport, safety & security.

**Funding Details:** The total amount available for a Canadian-based applicant for this funding opportunity is $353,000 (CAD), enough to fund approximately one (1) grant. This amount may increase if additional funding partners participate. The maximum amount per grant is $117,666 (CAD) per year for one (1) grant for a maximum of three (3) years.

---

**Child Health Foundation: Innovative Small Grants Program**

The objective of the Small Grants Program is to support innovative research, or innovative service projects, directed at improving the health and well-being of new-born infants during their first month of life. The CHF will consider a range of technologies and approaches including biomedical and social science projects, that show promise and may have widespread application. Projects must address child health issues in a developing country, or in the United States. All countries are eligible to apply.

**Funding Details:** A maximum of $5,000 for 1 year.

---

**Arthritis Society: Stars Career Development Award**

The Stars Career Development award has been created to firmly establish the career of early career investigators. This salary and research funding represents a three (3) year commitment by the Arthritis Society, together with an additional three (3) year commitment by the applicant’s Host Institution. The program is intended to promote creativity in all domains of arthritis-related research responsive to the Arthritis Society’s strategic priorities. Applicants should review the two research themes set out in the Arthritis Society’s 2015-2020 research strategy: (1) improving our understanding of arthritis and finding the cure, and (2) improving the care and management of arthritis.
Funding Details: The maximum award per application is $125,000 annually for up to three years ($375,000 total), with an additional 3 years of support from the Host Institution of an equal value. These awards are non-renewable. Please see additional details for more information.

Additional Details
Abstract Registration Deadline: May 22, 2019
Internal HRS Deadline: June 12, 2019
Sponsor Deadline: June 26, 2019

Weston Brain Institute Rapid Response Parkinson’s & Related Diseases
The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation. Meeting this challenge requires pioneering approaches to accelerating treatments. The Rapid Response: Canada program was created to provide seed funding to catalyze novel, high-risk, high-reward, translational research.

Projects must meet two conditions to be eligible:
- Be translational research that helps accelerate the development of therapeutics for neurodegenerative diseases of aging
- Be the development of a therapeutic and/or tool

Funding Details: A max of $300,000 over up to 18 months per project.

Additional Details
LOI Deadline: March 13, 2019
Internal HRS Deadline: July 2, 2019
Sponsor Deadline: July 16, 2019

Weston Brain Institute Transformational Research Parkinson’s & Related Diseases
The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation. Meeting this challenge requires pioneering approaches to accelerating treatments. The Transformational Research Program was created to provide significant support for larger, longer projects.

Projects must meet the following conditions to be eligible:
- Be translational research (excluding clinical trials and clinical trial sub-studies) that accelerates the development of therapeutics for neurodegenerative diseases of aging.
  - Clinical trials and clinical trial sub-studies should be submitted to the Early-Phase Clinical Trials or Rapid Response programs; however other translational research using humans or human samples/data is in scope.
- Be the development of a therapeutic and/or tool and/or complementary approaches

Funding Details: A max of $1,500,000 over a max of 3 years.

Additional Details
LOI Deadline: March 13, 2019
Internal HRS Deadline: July 2, 2019
Sponsor Deadline: July 16, 2019

The Michael J. Fox Foundation Grants Therapeutic Pipeline Program
The Michael J. Fox Foundation seeks applications with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care. Proposals must have a well-defined plan for moving toward clinical utility for Parkinson’s disease (PD) patients. The Therapeutic Pipeline Program is open to industry and academic investigators proposing novel approaches or repositioning approved or clinically safe therapies from non-PD indications. Part of our Edmond J. Safra Core Programs for PD Research, the Therapeutic Pipeline Program advances Parkinson’s disease therapeutic and
intervention development along the pre-clinical and clinical path (i.e., both drug and non-pharmacological therapeutics, including gene therapy, biological, surgical and non-invasive approaches).

**Funding Details:** A maximum of $500,000 for 1 to 2 years.

**Additional Details**

**Pre-Proposal Deadline:** April 19, 2019
**Internal HRS Deadline:** July 5, 2019
**Sponsor Deadline:** July 19, 2019 (By invitation only)

---

**The Michael J. Fox Foundation Grants: Assay Development and Validation for Quantifying Oligomeric Alpha-Synuclein**

The Michael J. Fox Foundation will award one-year grants for research to advance the development, optimization and validation of assays to quantify oligomeric alpha-synuclein in human body fluids. These biofluids may include blood, cerebrospinal fluid, saliva and tears. Prior research suggests that alpha-synuclein quantification in accessible body fluids may serve as a biomarker of disease diagnosis, target engagement, pharmacodynamic response and/or patient stratification.

- Immuno-assays should have a renewable source of the antibodies used. Optimization and/or adaptation of existent assays to different biological matrices will also be considered.
- Projects should propose to develop or optimize assays with superior performance in quantifying oligomeric alpha-synuclein and, at the end of the grant, should be able to present several performance parameters for further validation such as robustness, precision, trueness, uncertainty, limits of detection and quantification, dilutional linearity, parallelism, recovery, selectivity, and sample stability.

**Funding Details:** A maximum of $200,000 for 1 year.

**Additional Details**

**Pre-Proposal Deadline:** April 19, 2019
**Internal HRS Deadline:** July 5, 2019
**Sponsor Deadline:** July 19, 2019 (By invitation only)

---

**The Michael J. Fox Foundation Grants: Biology of Astrocytes in Parkinson’s Disease**

The Michael J. Fox Foundation will award one-year to 18-month grants for studies that explore the role of astrocytes in Parkinson’s disease (PD) pathology and the potential for astrocyte-focused therapeutics. The goals of this funding program are to further understanding of astrocyte biology in Parkinson’s and to rationalize the pursuit of astrocyte-specific targets and/or pathways for the treatment of the disease.

Preference will be given to applications that focus on or include the following:

- Role of astrocytes in initiating and/or propagating Parkinson’s disease pathology, including alpha-synuclein spread, dopaminergic neuron death, inflammation and senescence
- Consequences of dysfunction and/or mutations of common PD targets, including alpha-synuclein, LRRK2, GBA, PRKN and PINK1
- Manipulation of astrocyte activity and/or astrocyte-specific pathways to assess the potential of targeted astrocyte therapies on disease biology and/or symptoms
- Parkinson’s disease models with high construct validity to human PD, including patient-derived material (such as iPSCs or cerebral organoids) and/or well characterized animal models and primary cells; Examination of human brain samples to answer specific hypotheses is also acceptable
- Targets, pathways and mechanisms proposed for investigation should have reasonable links to PD.

**Funding Details:** A maximum of $150,000 for 1 year to 18 months.

**Additional Details**

**Pre-Proposal Deadline:** April 19, 2019
**Internal HRS Deadline:** July 5, 2019
**Sponsor Deadline:** July 19, 2019 (By invitation only)

---

**The Michael J. Fox Foundation Grants: Imaging Biomarkers to Track Disease Progression and Therapeutic Efficacy**
The Michael J. Fox Foundation will award one- to three-year grants to develop imaging markers for use in disease-modifying clinical trials. Imaging is a powerful tool that can be used to visualize the structure and function of the brain in living subjects. While a variety of imaging techniques are available, including positron emission tomography (PET), single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI), none have been demonstrated to be a sensitive, specific and reliable biomarker test for the presence and progression of PD.

Applications must focus on developing robust and precise imaging markers.

- Priority targets for this program are alpha-synuclein and neuroinflammation, but applications may focus on other promising therapeutic targets.
- Imaging modalities can include PET, SPECT and MRI.
- Projects should aim to develop novel imaging biomarkers as opposed to prospectively collecting data using existing technologies. Prospective data collection is appropriate only if a novel imaging technique or tracer is being tested. Novel data analysis techniques may be proposed but should utilize existing data sets.
- Examples of projects that are appropriate for this program include development of novel PET or SPECT tracers, early validation of new tracers, and development and validation of novel MRI techniques.

**Funding Details:** $750,000 for 1 to 3 years.

**Additional Details**

- **Pre-Proposal Deadline:** April 19, 2019
- **Internal HRS Deadline:** July 5, 2019
- **Sponsor Deadline:** July 19, 2019 (By invitation only)

---

**Alzheimer’s Drug Discovery Foundation (ADDF) and the Harrington Discovery Institute: ADDF-Harrington Scholar Program**

The objective of the ADDF-Harrington Scholar Program is to accelerate translation of innovative research with potential to prevent, treat, or cure Alzheimer’s disease under the funding priority, drug targets.

For the 2019 ADDF-Harrington Scholar RFP, targets related to proteostasis are of high priority.

These include, but are not limited to:

- Autophagy
- Lysosomal biogenesis
- Proteasomal degradation
- Post-translational modifications associated with proteostasis
- Protein folding/misfolding
- Endoplasmic reticulum stress
- Extracellular clearance

Although targets of proteostasis show high potential for the treatment of Alzheimer’s disease and related dementias, the field faces several challenges including a limited number of specific druggable targets for novel small molecules and a lack of translatable biomarkers that could be used in future clinical trials. For these reasons, there is a high interest in proposals that show promise in this area.

Other novel targets are encouraged. These include, but are not limited to:

- Neuroprotection
- Inflammation
- Vascular function
- Mitochondria & metabolic function
- APOE
- Epigenetics

**Funding Details:** A maximum $600,000 for 2 years.

**Additional Details**

- **LOI Deadline:** April 12, 2019
- **Internal HRS Deadline:** July 6, 2019
- **Sponsor Deadline:** July 19, 2019

---

**Weston Brain Institute Rapid Response Alzheimer’s & Related Diseases**
The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation. Meeting this challenge requires pioneering approaches to accelerating treatments. The Rapid Response: Canada program was created to provide seed funding to catalyze novel, high-risk, high-reward, translational research.

Projects must meet two conditions to be eligible:

- Be translational research that helps accelerate the development of therapeutics for neurodegenerative diseases of aging
- Be the development of a therapeutic and/or tool

**Funding Details:** A max of $300,000 over up to 18 months per project.

**Additional Details**

**LOI Deadline:** April 1, 2019  
**Internal HRS Deadline:** July 16, 2019  
**Sponsor Deadline:** July 30, 2019

---

**Weston Brain Institute Transformational Research Alzheimer’s & Related Diseases**

The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation. Meeting this challenge requires pioneering approaches to accelerating treatments. The Transformational Research Program was created to provide significant support for larger, longer projects.

Projects must meet the following conditions to be eligible:

- Be translational research (excluding clinical trials and clinical trial sub-studies) that accelerates the development of therapeutics for neurodegenerative diseases of aging.
  - Clinical trials and clinical trial sub-studies should be submitted to the Early-Phase Clinical Trials or Rapid Response programs; however other translational research using humans or human samples/data is in scope.
- Be the development of a therapeutic and/or tool and/or complementary approaches

**Funding Details:** A max of 1,500,000 over a max of 3 years.

**Additional Details**

**LOI Deadline:** April 1, 2019  
**Internal HRS Deadline:** July 16, 2019  
**Sponsor Deadline:** July 30, 2019

---


The objective of the Applied Research Competition is to 1) support studies that expand the body of knowledge related to autism intervention and treatment, 2) produce practical and clearly objective results, 3) impact public policy, and 4) provide outcomes that offer to enhance quality of life for persons with autism, and their families.

The OAR has placed an emphasis on research that addresses the following targeted areas:

- Community-Based Assessment and Intervention for Challenging Behavior.
- Effectiveness of Augmentative Communication Systems.
- Improving Access to and Effectiveness of Existing Systems and Services.
- Integrated Employment.
- Intersectionality, Equity and Diversity.
- Mental Health Assessment and Intervention.
- Mid-life and Older Adults.
- Residential/Community Services and Supports.

**Funding Details:** A maximum of $40,000 over 1-2 years.
Ontario Genomics: Genomics in Society Interdisciplinary Research Teams Program (GiSIRT)

Genome Canada has announced a Request for Applications (RFA) for the Genomics in Society Interdisciplinary Research Teams Program. This program aims to facilitate collaborations and dialogue among researchers and other key stakeholders to ensure effective and responsible translation of innovative genomics applications into sectors capable of transformation by genomics advances.

This program will support teams of researchers from diverse disciplines to address issues at the intersection of genomics and society. Research teams of at least three researchers from different disciplines investigating the advancement, adoption, evaluation, and governance of genomics research are encouraged to apply.

Proposal Focus Areas
Stream 1: proposals mainly impacting the human health sector
Stream 2: proposals mainly impacting the agriculture/agri-food and/or aquaculture/fisheries sectors
Stream 3: proposals mainly impacting the natural resources (forestry, energy, mining) and/or environment sectors

Proposals that address multiple sectors across two or three streams are also eligible to apply.

Funding Details: There is approximately $3 million available from Genome Canada. Approximately one-third of the available Genome Canada funding will be invested in each of the three streams as defined above with the goal of funding at least one team in each of the three streams. Genome Canada will contribute between $500,000 and $1 million with the amount of co-funding from eligible sources at least equal to the Genome Canada contribution. Successful teams will be awarded funding for a term of up to four years.

Additional Details
Internal HRS Deadline: August 9, 2019
Sponsor Deadline: Draft Applications: June 27, 2019. Final Applications: August 23, 2019

Arthritis Society: Strategic Operating Grants

The Strategic Operating Grant (SOG) program provides funding to support research proposals aligned with the Arthritis Society’s priorities. Consistent with the Arthritis Society’s 2015-2020 Research Strategy, Requests for Applications (RFAs) for SOGs will be made available by theme (typically one theme a year). The Arthritis Society will be accepting applications relevant to:

Strategic Theme I: Improving our understanding of arthritis and finding the cure
Research under this theme will seek to improve our understanding of the causes of arthritis in order to develop new approaches to alleviate the pain, prevent and/or slow the progression of disease, restore joint function, and eventually cure those affected by arthritis.

Research programs relevant to Strategic Theme I will have a main objective of:
- Understanding arthritis and arthritis pain pathophysiology and identifying therapeutic opportunities;
- Identifying and characterizing risk, and causal factors and/or development of arthritis and arthritis pain (including: biologic and endogenous factors; physical environment; and, psychological, social and economic factors);
- Discovering, developing and evaluating diagnostic (early detection), prognostic and predictive markers and technologies (such as imaging, diagnostic and other assessment tools) of disease (including: biomarker discovery and evaluation);
- Discovering, developing and evaluating potential therapeutic interventions in model systems and preclinical settings. (Including: pharmaceuticals; biologics; gene/cell/tissue therapies; medical devices; surgery (including joint replacement); and physical agents – including physical therapy, radiotherapy, ultrasound, laser and phototherapy).

Funding Details: The maximum grant per application is $120,000 annually for up to three (3) years ($360,000 total). These grants are non-renewable.

Additional Details
LOI Deadline: April 15, 2019
Internal HRS Deadline: August 9, 2019
Sponsor Deadline: August 25, 2019
Canadian Cancer Society: Impact Grants

The Impact Grant program supports significant progression in cancer research programs that are anywhere in the continuum from basic, high impact discovery to translational work of direct relevance to the clinic and beyond. Impact Grants aim to accelerate and focus the knowledge gained from scientific findings, in the short- to medium-term, into outcomes that will significantly advance understanding of cancer and improve scientific knowledge, which will result in optimized patient care, improved cancer treatment or reduced cancer burden. Impact Grants provide funding to support ideas that promote major advancements in research programs, whether at the fundamental discovery stage (such as studies involving model organisms that demonstrate potential for impact) through to applied research (such as patient or population-based proposals). Applications are encouraged from, but not limited to, the areas of biomedical, clinical, health services, and social and population health research.

Impact grants are not intended to support incremental scientific advances and are not intended to solely support research infrastructure.

Impact grants have been created to cultivate and support programs in cancer research that have the potential to make a significant impact on the burden of disease in patients and populations. The goal of the CCS Research Impact Grant program is to provide a mechanism for scientists to adopt innovations and accelerate the application of new knowledge to address problems in cancer research that have the potential for practical application.

**Funding Details:** There is one competition per year. It is anticipated that approximately 7 grants will be awarded in this competition. Note: Budgets awarded will not exceed $300,000 per year, to a maximum of $1,500,000 per grant. The grant term is up to 5 years. Grants will be renewable at the end of their term.

Funding will be provided to support the direct costs of a defined research program, including supplies, expenses, wages and equipment associated with the proposed work. Indirect costs will not be considered eligible expenses. Equipment requests of up to $150,000 can be included within the proposed budget.

**Additional Details**
**LOI Deadline:** April 17, 2019
**Internal HRS Deadline:** August 27, 2019
**Sponsor Deadline:** September 10, 2019

---

**Canadian Cancer Society: Travel Awards**

A limited number of Travel Awards to PhD or MD/PhD students, and post-doctoral/medical/clinical fellows are available. The purpose of this program is to defray the travel costs associated with making a scientific presentation as a first author or presenter at a conference, symposium or other appropriate professional meeting.

**Funding Details:** It is anticipated that up to 10 Travel Awards will be awarded in each competition (30 awards per year).

Note: Eligible expenses include: 1) Conference registration fees; 2) Accommodations; and 3) Transportation, and will not exceed $2,000.

**Additional Details**
**Sponsor Deadline:** Applications are being accepted on a rolling basis January 1, May 15 and September 15 annually.

---

**Canadian Cancer Society: Junior Investigator Grant Panel Travel Award**

Application guides can be found on the [EGrAMS documentation for applicants](#) page.

The Canadian Cancer Society is pleased to offer a special initiative to allow junior investigators in cancer research to gain knowledge and understanding of the Canadian Cancer Society peer-review process. During the year, through different funding opportunities, applications spanning all disciplines of cancer research are evaluated and ranked for funding.

Selected investigators from across Canada will be provided funds to reimburse travel costs to Toronto to observe a grant panel meeting. This unique opportunity will provide junior faculty members with an “inside look” at how research grants are reviewed in order to help structure their own grant proposals in future.

Eligible applicants are investigators in cancer research at the end of their Post-doctoral fellowship or within the first few years of their academic appointment. Priority will be given to those who have yet to be awarded a grant from a Canadian granting agency. Applications for these limited funds will be accepted via EGrAMS and require Department or Institution Head sign-off prior to submission.

Please view the list of [current grant panels](#) for more information on available panels.
Sponsor Deadline: Applications are being accepted on a rolling basis.

SickKids Foundation: Community Conference Grants
The objective is to bring together families with researchers and clinicians for medical presentations, workshops, symposia and family-oriented discussions. The conference helps to ensure families receive access to the most up-to-date information regarding their children’s health. The grant will support events which are organized by and/or for families with children with health challenges, including, but not limited to children with acute illness, chronic illness and disabilities.

Funding Details: Awards are limited to an annual maximum request of $5,000. The Foundation will fund a maximum of three consecutive annual events organized by any single organization.

Additional Details
Sponsor Deadline: Applications are being accepted on a rolling basis January 31, May 31 and September 30 annually.

Cancer Research Society: Translational Research Partnership Program
The Translational Research Partnership Program supports collaborative projects in cancer research to help accelerate the development of new treatments and/or technologies for the benefit of patients. Our Translational Research Partnership strategy is bold and ambitious. We aim to break down the boundaries between research disciplines, which may include researchers from non-cancer backgrounds, in order to find innovative solutions to prevent, detect and treat cancer. We partner with a range of organizations to maximize the impact of research on patient outcomes.

Projects must meet the following conditions:
• Be translational research and may include clinical trial studies
• Basic research projects are out of scope
• Aim the development of a therapeutic and/or novel technologies
• Have excellent preliminary data to support the proposed project

The research team must consist of at least one principal investigator and one co-investigator. The inclusion of a variety of non-cancer disciplines is encouraged to drive the development of novel technologies and to take thinking from other fields that have not yet been applied to cancer.

All projects are evaluated based on the following criteria:
• Scientific excellence and innovativeness of proposed project
• Expertise of the multidisciplinary team
• Quality of preliminary data and feasibility
• Financial partner’s engagement
• Anticipated benefits for cancer patients

Funding Details: A maximum of $1,500,000 over up to 3 years per project of which up to 50% may come from the Cancer Research Society

Additional Details
Sponsor Deadline: Applications are being accepted on a rolling basis.

HHS: Clinical Health Professional Travel Awards
The Clinical Health Professionals Research Travel Award provides support for eligible non-physician Health Professionals to present their work at a scientific meeting of relevance to their practice/research.

Funding Details: Up to six awards on a competitive basis will be given within a calendar year, and are each valued up to a maximum of $2,500 for a national conference or $3,500 for international (funds in Canadian dollars).

Additional Details
Sponsor Deadline: Applications are being accepted on a rolling basis.

The Ontario HIV Treatment Network (OHTN), Endgame Funding Program: Community-Based Research and Evaluation (CBR&E) Awards
The OHTN Community-Based Research & Evaluation Fund (CBR & E Fund) is designed to help achieve the mission of the OHTN; to improve the health and well-being of people living with and at risk of HIV in Ontario, through a network that promotes research and
evidence to drive change. The CBR & E Fund will assist communities by supporting both the production and discovery of knowledge through community-based research, and the use of evidence to drive programming through participatory program evaluation.

OHTN is committed to funding scientifically rigorous, community relevant research that will have a short-to medium-term impact on those most affected by HIV in Ontario:

- People living with HIV/AIDS
- Gay men and other men who have sex with men, including gay, bi, and queer trans men, youth and newcomers
- African, Caribbean and Black men and women, including youth
- Aboriginal men and women, including youth
- Men and women who use drugs
- Women, including trans women, who are at risk (e.g. have unprotected sex or share drug equipment with people from the populations listed above)

The CBR & E fund will provide grant support to eligible community-initiated HIV research and evaluation projects that explore questions of importance to community-based organizations, and have the potential to have a meaningful impact on those most affected by HIV in Ontario in the next 2-5 years.

**Funding Details:** $25,000 to $50,000 for 1 year.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis March 1, June 7, September 6 and December 6, 2019.

---

**Ontario Brain Institute (OBI): Event Funding Program**

The Ontario Brain Institute (OBI) is committed to working together with brain health-related organizations in order to increase the capacity of their work in Ontario. The program especially looks to support events that embody OBI’s principles of integration and collaboration.

**Funding Details:** Up to $5,000.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis in January, May and September.

---

**Crohn’s & Colitis Foundation: IBD Ventures**

Is your organization engaged in the discovery or development of a novel product with the potential to help patients with inflammatory bowel diseases? If so, we want to hear from you!

The Crohn's & Colitis Foundation seeks to accelerate the development of products that aim to improve the quality of life of patients with inflammatory bowel diseases. Toward that end, the Foundation has launched IBD Ventures, a new program and dedicated funding mechanism to support product-oriented research and development. Companies and academic investigators can apply.

**Funding Details:** Up to $500,000 per project per year will be considered. In addition, funded programs will be offered accelerator resources and advising.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis.

---

**Ontario Genomics: Genomic Applications Partnership Program (GAPP)**

The Genomic Applications Partnership Program (GAPP) funds downstream research and development (R&D) projects that address real world opportunities and challenges defined by “Receptor” organizations such as industry, government, or not-for-profit entities. These organizations should be committed to commercializing or implementing the outcomes of the project.

Projects are led by the Receptor organization (Canadian or international) but are active collaborations with a Canadian academic researcher. These projects are co-funded by Receptors and other stakeholders and must have the potential to generate significant social and/or economic benefits for Canada.

The GAPP aims to:

- Accelerate the application of Canadian genomics-derived solutions from academia to real-world opportunities and challenges defined by industry, not-for-profit and public-sector Receptors.
- Channel Canada’s genomics capacity into sustainable innovations that benefit Canadians.
- Enhance the value of Canadian genomics technologies by de-risking and incentivizing follow-on investment from industry and other partners.
- Foster mutually beneficial collaboration and knowledge exchange between Canadian academia and technology receptors.
**Weston Brain Institute Postdoctoral Scholars at Oxford**
The Weston Brain Institute Postdoctoral Scholars at Oxford program supports top-tier Canadian postdoctoral scholars by providing international training at the University of Oxford and affiliation with Merton College. Prior to submitting an application, candidates should independently identify a host lab and potential supervisor at the University of Oxford who agrees to supervise them if awarded. Awardees will receive salary support for their postdoctoral positions at Oxford.

**Funding Details:** £57,000 per year (£44,000 per year + benefits) for 2 years.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis, until 2 positions at a time are filled.

---

**Alzheimer’s Drug Discovery Foundation: Prevention Beyond the Pipeline**

**Consortium of Cohorts for Alzheimer's Prevention Action (CAPA):** Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. More information here. [More information here](https://www.addf.org/capac).

**Comparative Effectiveness Research:** For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see Box 1 in the ADDF 2016 position paper). Methods may include randomized trials or epidemiology.

**Cognitive Decline and Cognitive Reserve:** Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.

**Funding Details:** $50,000 to $100,000 for epidemiological analyses based on scope of research. Up to $3 million for clinical trials based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

**Additional Details**

**LOI Deadline:** Accepted on a rolling basis January 18, April 12, July 12, October 11.

**Sponsor Deadline:** Accepted on a rolling basis February 8, May 10, August 9, November 8.

---

**Alzheimer’s Drug Discovery Foundation: Drug Discovery Program**
The Alzheimer’s Drug Discovery Foundation (ADDF) has long recognized the need to bridge the translational funding gap between early-stage drug discovery and clinical development for Alzheimer’s disease, related dementias, and cognitive aging by supporting promising therapeutic approaches.
The Drug Discovery RFP supports:

- Novel drug programs aiming to advance novel lead molecules to the clinical candidate selection stage. This includes small molecules and biologics (e.g., antibodies, peptides, gene therapies).
- Repurposed/repositioned programs aiming to build preclinical evidence in relevant animal models for repurposed drugs (existing drugs that are approved for other diseases and conditions) and repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved).

**Funding Details:** $150,000-$600,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. One year with potential for follow-on funding. Multi-year proposals can be considered.

**Additional Details**

**LOI Deadline:** Accepted on a rolling basis January 18, April 12, July 12, October 11.

**Sponsor Deadline:** Accepted on a rolling basis February 8, May 10, August 9, November 8.

### Alzheimer’s Drug Discovery Foundation: Neuroimaging & CSF Biomarker Development Program

Given the pathological heterogeneity of Alzheimer’s disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology.

This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to:

- Clearly demonstrate target engagement for novel therapeutics
  The development of biomarkers that can serve as measures of target engagement for novel targets such as neuroinflammation features (e.g. microglial activity, cytokine production, astrocytic activity), synaptic damage, metabolic activity, mitochondrial dysfunction, vascular health and epigenetic changes, among others, are of particular interest. High priority will be given to projects developing biomarkers that can be used in combination with therapies currently in development and serve as companion biomarkers.

- Detect signs of disease earlier and monitor progression
  We are seeking programs developing sensitive biomarkers that can detect disease earlier than currently available tests. This includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI) or MCI to Alzheimer’s disease. We also seek prognostic markers that can predict rates of cognitive decline.

- More accurately diagnose and distinguish between dementia subtypes
  Many types of dementias can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.

**Funding Details:** $150,000-$600,000 based on stage and scope of research. Larger amounts will be considered for PET ligand development for regulatory or clinical work. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. One year with potential for follow-on funding. Multi-year proposals can be considered.

**Additional Details**

**LOI Deadline:** Accepted on a rolling basis January 18, April 12, July 12, October 11.

**Sponsor Deadline:** Accepted on a rolling basis February 8, May 10, August 9, November 8.

### McMaster University, McMaster Institute for Research on Aging (MIRA), Canadian Longitudinal Study on Aging (CLSA): Call for Proposals

The CLSA is a large, national, long-term study of more than 50,000 men and women who were between the ages of 45 and 85 when recruited. These participants will be followed until 2033, or death. The aim of the CLSA is to find ways to help us live long and live well, and understand why some people age in healthy fashion while others do not.

Researchers must notify Laura Harrington, Managing Director, MIRA, of their intent to apply for CLSA data access to be considered for MIRA funding. MIRA funds are allocated only to projects that do not have any other funding for this purpose.

MIRA membership is required to be eligible.

Data access applications are accepted three times per year.

**Funding Details:** MIRA can support access fees of $3,000 for a maximum 10 applications.


**Sponsor Deadline:** Ongoing
McMaster University, McMaster Institute for Research on Aging (MIRA), Labarge Centre for Mobility in Aging (LCMA): Matching Funds for Research Opportunities

The McMaster Institute for Research on Aging (MIRA) aims to optimize the health and longevity of the aging population through leading-edge research, education and stakeholder collaborations. The institute intends to amplify McMaster’s strength in aging-focused research through stimulating new partnerships, facilitating access to research funding, raising the profile of McMaster’s research platforms, and building capacity among students and faculty members. In order to improve the positioning of McMaster’s researchers in external funding competition, MIRA and the Labarge Centre for Mobility in Aging (LCMA) have allocated funding that could be used to match or leverage external funds. This process is intended to be used for requests related to externally funded, peer-reviewed grant competitions that require a matching component.

Funding Details: Maximum $100,000 (total cash and/or in-kind) non-renewable funding anticipated support 1-2 projects per year.

Additional Details
Sponsor Deadline: Ongoing

MITACS Globalink Research Award

The Mitacs Globalink Research Award provides funding for senior undergraduate and graduate students, and postdoctoral fellows in Canada to conduct 12–24-week research projects at universities overseas. The following opportunities support travel and research from Canada to universities in: Australia, Brazil, China, EU member countries: In France, both universities and Inria Research Centres are eligible host institutions, Israel, India, Japan, Korea, Mexico, Norway, Saudi Arabia, Tunisia, United Kingdom, United States.

Funding Details: $6,000 to conduct 12-24-week research projects at universities overseas.

Additional Details
Sponsor Deadline: Ongoing

MITACS Accelerate Fellowship

The Mitacs Accelerate Fellowship provides a long-term funding and internship option for master’s and PhD students. Recipients can also access professional development training that helps them ensure project success and gain in-demand career skills. Interested applicants can apply for the Accelerate Fellowship at any time. All other Accelerate program guidelines apply.

Funding Details:
- **Master’s students** - $40,000 total research award for 18 mos. Minimum intern stipend is $30,000 and partner organization contribution is $18,000
- **PhD students** - $80,000 total research award for 36 mos. Minimum intern stipend is $72,000 (24,000/year) and partner organization contribution is $36,000

Additional Details
Sponsor Deadline: Ongoing

*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

Weston Brain Institute: Big Ideas

Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments.

Based on success of previous programs, the Institute is expanding our support to new formats while maintaining the same mandate of accelerating the developments of therapeutics for neurodegenerative diseases of aging through translational research.

The Institute is considering supporting a large-scale, pivotal project to significantly advance research in our field. With this call, we are seeking to identify highly impactful ideas for consideration. Of particular interest are ideas that will establish Canada as the world leader in a particular area.

Goal: To support a large-scale, pivotal project that will significantly and sustainably advance research in the field of translational research on neurodegenerative diseases of aging.

Funding Details: From $5,000,000 to $20,000,000.

Additional Details
Sponsor Deadline: Ongoing

Weston Brain Institute: Early Phase Clinical Trials: Canada
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Early Phase Clinical Trials: Canada program was created to provide funding support for clinical trials and clinical trial sub-studies that have excellent preliminary data. Eligible Principal Applicants must be at or above the level of Assistant Professor or equivalent and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Co-applicants and Collaborators must be at the post-doctoral level or above and can be working outside Canada.

An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be forwarded to those invited. Applicants can expect to receive the outcome of their LOI application approximately 2 months after submission.

**Funding Details:** A maximum of $1,500,000 per project over up to 4 years.

**Additional Details**

**Sponsor Deadline: Ongoing**

---

**OCE Voucher for Innovation and Productivity II (VIP II) Program**

The VIP II program helps established Ontario-based companies develop, implement and commercialize technical innovations by supporting partnerships with publicly-funded post-secondary institutions. Projects funded through VIP II address company needs by enabling the development of new products and/or processes, or facilitating productivity improvements, by leveraging post-secondary institutions’ skills and resources. Projects must ultimately help generate new revenues and create high-value jobs for Ontario companies. You can also leverage your sponsor’s contribution through the NSERC CRD program for additional research funds.

**Funding Details:** The VIP II program supports collaborations between companies and publicly-funded post-secondary institutions for durations of 12 and 24 months to a maximum of $150,000.

**Additional Details**

**Sponsor Deadline: Ongoing**

*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**MITACS Accelerate Program**

Canada’s premiere research internship program provides interns with the opportunity to transfer their skills from theory to real-world application, while companies gain a competitive advantage by accessing high-quality research expertise. Interns spend approximately half their time on-site with the industry partner; the remainder is spent at the university advancing the research under the guidance of a faculty supervisor. Not-for-profit organizations are eligible.

**Funding Details:** Funding starts at $15,000

**Additional Details**

**Sponsor Deadline: Ongoing**

*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP): Discovery Award**

The intent of the PRMRP Discovery Award is to support innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a sound scientific rationale and study design. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Innovation is the most important review criterion. Innovative research may introduce a new paradigm, look at existing problems from new perspectives, or exhibit other highly creative qualities. Research that represents an incremental advancement on previously published work is not considered innovative. The following list, although not all-inclusive, provides examples of research that is not innovative:

- Exploring a previously tested hypothesis in a different cell line or in a new population
- Using a published series of in-vitro assays to further characterize a model system
- Incorporating known biomarkers into in-vivo or clinical models of the disease or condition
- Investigating the next logical step or continuation of a previous research project
- Proposing work that is an incremental advancement of published data
Inclusion of preliminary data is not required, but is allowed. The strength of the proposed research should be based on sound scientific rationale and logical reasoning. The presentation of substantial preliminary data suggests that the proposed research project would be more appropriately submitted to a different award mechanism. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects. Absence of preliminary data will not negatively affect scientific or programmatic review of the application.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 PRMRP Discovery Award will not exceed $200,000.

**Additional Details**

**LOI Deadline:** March 28, 2019 (A pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** March 28, 2019
**Sponsor Deadline:** April 11, 2019

---

**Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCRP): Exploration Hypothesis Development Award**

The Exploration – Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.

The following are important aspects of the Exploration – Hypothesis Development Award:

- **Innovation:** Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of this award mechanism.
- **Impact:** The primary goal of this mechanism is to pioneer transformative research that could lay the foundation for a new direction in the field of TSC.
- **Feasibility:** Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 TSCRCP Exploration – Hypothesis Development Award will not exceed $150,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** April 18, 2019 (A pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** April 25, 2019
**Sponsor Deadline:** May 9, 2019

---

**Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCRCP): Idea Development Award**

The Idea Development Award promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale.

The following are important aspects of the Idea Development Award:

- **Impact:** Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care.
- **Innovation:** Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (the next logical step) is not considered innovative.
- **Preliminary Data:** Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, and/or data from the published literature that are relevant to TSC and the proposed research project, are expected.
New Investigator Option: The FY19 TSCRP Idea Development Award mechanism encourages applications from investigators in the early stages of their TSC research career. The New Investigator Option is designed to support the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in the field of TSC research. Applications from New Investigators and Established Investigators will be peer and programatically reviewed in separate groups. PIs applying under the New Investigator category are strongly encouraged to strengthen their applications through collaboration with investigators experienced in TSC research and/or possessing other relevant expertise as demonstrated by a record of funding and publications.

Funding Details: The anticipated direct costs budgeted for the entire period of performance for an FY19 TSCRP Idea Development Award will not exceed $450,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Additional Details
LOI Deadline: April 18, 2019 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: April 25, 2019
Sponsor Deadline: May 9, 2019

Department of Defense (DoD) Tuberous Sclerosis Complex Research Program (TSCRP): Clinical Translational Research Award

The Clinical Translational Research Award supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC. Projects supported by this award mechanism may include studies moving from preclinical to clinical research (including a pilot clinical trial) and/or the reverse, analyzing human anatomical substances and/or data associated with clinical trials (such as correlative studies). Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of PK/PD are of particular interest to the FY19 TSCRP.

Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. Preclinical studies may be appropriate but must include a clinical component. Projects that are exploratory and/or strictly animal research will not be considered for funding.

Developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism can be found in the report of the National Cancer Institute Translational Research Working Group (http://clincancerres.aacrjournals.org/content/14/18/5664.full). These pathways are comprehensive and span the entire translational research continuum from bench to bedside to bench.

The following are important aspects of the Clinical Translational Research Award:

- **Translation:** The application should clearly state how the proposed research project will expand upon promising, preclinical, and/or clinical research findings to move the field closer to a clinical application by the end of the study. If the proposed research includes both preclinical research and a pilot clinical trial, the application should explain how the preclinical research and pilot clinical trial aims are connected and necessary to advance the research toward clinical implementation.
- **Impact:** Proposed studies should have the potential to improve the diagnosis, prognosis, or treatment of TSC by: ○ Likely having a major impact on therapy by applying promising and well-founded laboratory or other preclinical or clinical research findings to the care of patients, and/or ○ Leveraging information from ongoing or completed clinical trials to address knowledge gaps in resulting outcomes, validate key research findings and expand upon potentially transformative results, or investigate novel findings.
- **Feasibility:** The application should demonstrate that the investigators have access to the necessary specimens, data, and/or intervention, as applicable.
- **Preliminary Data:** Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on the application, and/or data from the published literature that are relevant to TSC and the proposed research project, are required.

Projects including correlative studies: The FY19 TSCRP Clinical Translational Research Award may support correlative studies that are associated with an ongoing or completed clinical trial. The application should demonstrate access to the necessary specimens and/or data of the proposed cohort. Appropriate access must be confirmed at the time of application submission. See Attachment 10, Letter(s) Confirming Access to Specimens and/or Data. Projects including a pilot clinical trial: The FY19 TSCRP Clinical Translational Research Award may support a pilot clinical trial where limited clinical testing of a novel intervention is necessary to inform the next step in the continuum of translational research.
New FY19 definition for clinical trial: A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

The applicant conducting the trial must post an informed consent form used to enroll subjects on a publicly available Federal Web site in accordance with federal requirements (49 CFR Part 11).

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 TSCRP Clinical Translational Research Award will not exceed $600,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. The CDMRP expects to allot approximately $1.92M to fund approximately two Clinical Translational Research Award applications.

**Additional Details**

**LOI Deadline:** April 18, 2019 (A pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** April 25, 2019
**Sponsor Deadline:** May 9, 2019

---

**Department of Defense (DoD) Military Burn Research Program (MBRP): Idea Development Award**

The MBRP Idea Development Award (IDA) mechanism is being offered for the first time in FY19. The intent of the FY19/20 MBRP IDA is to support highly impactful and military relevant research in the field of burn wound care. Applications proposing applied research and/or preclinical research will be considered for funding. Fundamental basic research and clinical studies will not be considered for funding.

Burns have comprised some 5%-20% of the casualties sustained in post-World War II conflicts. 1 Potential future conflicts may cause a rise in the number of burn injuries sustained by Service members and the general public should those conflicts occur in rural areas, austere combat zones, and in mass casualty events, whereby medical resources are limited and/or access to medical care is delayed for hours, days, or weeks. In order to prepare the military and the Nation for such potential future conflicts, the FY19/20 MBRP is soliciting research to provide burn care solutions closer to the point of injury for the pre-hospital setting and for a prolonged field care scenario.

The North Atlantic Treaty Organization (NATO) defines prolonged field care (PFC) as field trauma care extended beyond doctrinal timelines until the patient can be transported from the point of injury to an appropriate level of care. PFC has been identified as a high priority capability gap across the Army and other Services. Additional information regarding PFC can be found in the following articles, Prolonged Field Care: Beyond the ‘Golden Hour’ 2 and Prolonged Field Care the New Normal says Army, MRMC Brass. 3

Although encouraged, applications submitted to the FY19/20 MBRP IDA are not required to address PFC. However, the proposed research must be relevant to active duty Service members and/or Veterans. Outcomes of funded projects are expected to also benefit military beneficiaries and the American public.

Inclusion of preliminary and/or published data relevant to the proposed research is required. To be competitive, the application must include a sound scientific rationale, logical reasoning, and a well-formulated, testable hypothesis.

**Funding Details:** The anticipated total costs budgeted for the entire period of performance for an FY19/20 MBRP IDA will not exceed $500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** April 17, 2019 (A pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** June 26, 2019
**Sponsor Deadline:** July 10, 2019

---

**Department of Defense (DoD) Military Burn Research Program (MBRP): Clinical Translational Research Award**

The MBRP Clinical Translational Research Award (CTRA) is intended to support clinical research projects that are likely to have a major impact on therapy by applying promising and well-founded laboratory, preclinical, or clinical research findings to the care of the burn-injured patient.

Burns have comprised some 5%-20% of the casualties sustained in post-World War II conflicts. 1 Potential future conflicts may cause a rise in the number of burn injuries sustained by Service members and the general public should those conflicts occur in rural areas, austere combat zones, and in mass casualty events, whereby medical resources are limited and/or access to medical care is delayed for hours, days, or weeks. In order to prepare the military and the Nation for such potential future conflicts, the FY19/20 MBRP is soliciting research to provide burn care solutions closer to the point of injury for the pre-hospital setting and for a prolonged field care scenario.
The North Atlantic Treaty Organization (NATO) defines prolonged field care (PFC) as field trauma care extended beyond doctrinal timelines until the patient can be transported from the point of injury to an appropriate level of care. PFC has been identified as a high priority capability gap across the Army and other Services. Additional information regarding PFC can be found in the following articles, Prolonged Field Care: Beyond the ‘Golden Hour’2 and Prolonged Field Care the New Normal says Army, MRMC Brass. 3

Although encouraged, applications submitted to the FY19/20 MBRP CTRA are not required to address PFC. However, the proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

Funding from this award mechanism must support clinical research involving human subjects; animal research is not allowed under this funding opportunity. Principal Investigators (PIs) seeking funding for a preclinical research project should consider the Therapeutic Idea Award if appropriate.

**Funding Details:** The anticipated total costs budgeted for the entire period of performance for an FY19/20 MBRP CTRA will not exceed $1.55M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

LOI Deadline: **April 17, 2019** (A pre-application is required and must be submitted through eBRAP)

Internal HRS Deadline: **June 26, 2019**

Sponsor Deadline: **July 10, 2019**

---

**Department of Defense (DoD) Amyotrophic Lateral Sclerosis Research Program (ALSRP): Therapeutic Development Award**

The Therapeutic Development Award supports research ranging from validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited ALS experience are strongly encouraged to collaborate with those having substantial expertise in ALS research and/or ALS model systems. Examples of activities that will be supported by this award include:

- Confirmation of candidate therapeutics obtained from screening or by other means, including optimization of potency and pharmacological properties and testing of derivatives and sister compounds
- Validation of early pilot studies, including the use of multiple ALS model systems and/or replicating preliminary data with more time points or additional doses
- Studies on formulation and stability leading to Good Manufacturing Practice (GMP) production methods
- IND-enabling studies, to include compound characterization, absorption, distribution, metabolism, and excretion (ADME) studies, and dose/response and toxicology studies in relevant model systems

**Funding Details:**

- The anticipated direct costs budgeted for the entire period of performance will not exceed $1,250,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding $1,250,000 direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.
- A Therapeutic Development Award application including Therapeutically Relevant Marker Option that does not meet the criteria specified for that option may be funded at the lower maximum direct costs of $1,000,000, i.e., at the level of the standard Therapeutic Development Award as described above.

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award. The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 2 years.

**Additional Details**

LOI Deadline: **March 22, 2019** (A pre-application is required and must be submitted through eBRAP)

Internal HRS Deadline: **July 11, 2019**

Sponsor Deadline: **July 25, 2019**

---

**Department of Defense (DoD) Amyotrophic Lateral Sclerosis Research Program (ALSRP): Therapeutic Idea Award**

The Therapeutic Idea Award is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Projects that focus primarily on investigating the pathophysiology of ALS are not within the scope of this Funding Opportunity. Development and/or modification of preclinical model systems or the application of high-through-put screens to define or assess lead compounds for ALS treatment are of interest. Development of methods to adequately measure target binding and
proximal downstream effects (target engagement) and the potential for undesirable activities at related but unintended targets (selectivity) are also encouraged. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach. All proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality.

Innovation and impact are important aspects of the Therapeutic Idea Award. Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or technologies, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS. Impact may be near-term or long-term, but must be significant and move beyond an incremental advancement.

**Funding Details:** The maximum period of performance is 2 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $500,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding $500,000 direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.

**Additional Details**

**LOI Deadline:** March 22, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** July 11, 2019

**Sponsor Deadline:** July 25, 2019

---

**Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Pilot Award**

The OCRP Pilot Award supports the exploration of innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. The proposed research must demonstrate a clear focus on ovarian cancer (e.g., using tissues, cell lines, datasets, or appropriate animal models). The proposed research should include a testable hypothesis based on strong scientific rationale and serve as a catalyst to expand or modify current thinking about and/or approaches in ovarian cancer. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

Inclusion of preliminary data is not required, but allowed. The strength of the application should be based on sound scientific rationale and logical reasoning. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects. Clinical trials will not be supported by this award mechanism.

Innovation is the most important review criterion. Innovative ideas or approaches, if proven correct, will provide new paradigms or insights or technologies or applications that have the potential to meet the OCRP mission of supporting patient-centered research to prevent, detect, treat, and cure ovarian cancer.

The following list, although not all-inclusive, provides examples of research that is not innovative:

- Exploring a previously tested hypothesis in a different cell line or in a new population
- Using a published series of in vitro assays to further characterize a model system
- Incorporating known biomarkers into in vivo or clinical models of ovarian cancer
- Investigating the next logical step or continuation of a previous research project
- Proposing work that is an incremental advancement of published data

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 OCRP Pilot Award will not exceed $250,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** April 23, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** July 10, 2019

**Sponsor Deadline:** July 24, 2019

---

**Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Investigator-Initiated Research Award**

The OCRP Investigator-Initiated Research Award is intended to support high-impact research that has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive.

Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project.
The proposed research must be relevant to the health of active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 OCRP Investigator-Initiated Research Award will not exceed $450,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** April 23, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** July 10, 2019

**Sponsor Deadline:** July 24, 2019

**Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Ovarian Cancer Academy Award - Early-Career Investigator**

The OCRP Ovarian Cancer Academy Award mechanism, which was initially created in FY09, is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the Ovarian Cancer Academy (OCA) is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment.

The OCA is a virtual career development and research training platform that consists of EarlyCareer Investigators (ECIs) and their Designated Mentors from different institutions, and an Academy Dean and Assistant Dean. The OCRP Ovarian Cancer Academy – Early-Career Investigator Award is not a traditional career development award; the ECI is expected to participate in monthly webinars and annual workshops and to communicate and collaborate with other members of the Academy (other ECIs, Mentors, Dean, Assistant Dean) as well as with the advocacy community. Since the inception of the Academy, the Academy’s ECIs have presented at and chaired sessions for ovarian cancer-specific symposia and served on symposia review committees. They have also served as peer reviewers for the Department of Defense (DoD) OCRP and other funding agencies.

The Academy Leadership, Dean and Assistant Dean, serves as a resource for the ECIs and Mentors, assessing the progress of the ECIs, and facilitating communication and collaboration among all of the ECIs and Mentors, as well as with national research and advocacy communities. In addition to fostering the scientific development, the Academy, through its Leadership, provides for professional and leadership development of the ECIs to include skills and competencies needed to fund and manage a productive laboratory. Information about the Academy is available through the Ovarian Cancer Academy video and OCRP Glitz Sheet on the OCRP website.

This FY19 Program Announcement/Funding Opportunity is soliciting additional ECIs to join the existing Academy. This award mechanism enables the ECI (the investigator named as the Principal Investigator [PI] on the application) to pursue an ovarian cancer project that may be basic, translational, and/or clinical research, or a clinical trial under the guidance of a Designated Mentor. The Designated Mentor is not required to be at the same institution as the ECI.

The OCRP encourages applications from ECIs whose ability to commit to conducting ovarian cancer research is limited by minimal resources or a lack of resources, such as a qualified Designated Mentor at his/her institution, access to ovarian cancer research tools, opportunities for establishing collaborations, or other obstacles.

Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from the ovarian cancer research field.

The ECI, who will be the PI of the application, must be in the early-career stage. This award provides the ECI with funding, networking and collaborative opportunities, and research experience necessary to develop and sustain a successful, independent career at the forefront of ovarian cancer research. This award also provides support and protected time for the ECI for 4 years of intensive research under the guidance of a Designated Mentor experienced in ovarian cancer research. Although the OCA will serve as a conduit to share knowledge and research experience among all Academy members, the ECI and Designated Mentor will be responsible for developing the ECI’s career development plans and for designing and executing the proposed research. The ECI must clearly articulate his/her commitment to a career as an ovarian cancer researcher and to participating in and contributing to the growth of the OCA.

The Designated Mentor must have a strong record of mentoring and training early-career investigators. In addition to being a Designated Mentor to an ECI, the Mentor must agree to serve as a secondary Mentor to another OCA-ECI. With the goal to expand and enrich the mentorship capabilities of the Academy, current OCA Designated Mentors can only be a Designated Mentor to one OCA-ECI; thus, current OCA Designated Mentors cannot be named as a Designated Mentor in an FY19 application unless the period of performance of the current OCA-ECI award ends no later than July 2020. In the same manner, the Dean and Assistant Dean of the Academy cannot be listed as Designated Mentors.
The ECI and Designated Mentor are required to attend a DoD OCRP biennial multi-day Academy workshop and, in alternate years, a DoD OCRP Academy 1-day workshop.

The proposed research must be relevant to the health of active duty Service members, Veterans, military beneficiaries, and/or the American public.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 OCRP Ovarian Cancer Academy – Early-Career Investigator Award will not exceed $725,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** April 30, 2019 (A pre-application is required and must be submitted through eBRAP)  
**Internal HRS Deadline:** July 17, 2019  
**Sponsor Deadline:** July 31, 2019

**Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Ovarian Cancer Academy Dean and Assistant Dean (Leadership) Award**

The OCRP Ovarian Cancer Academy Award mechanism, which was initially created in FY09, is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the Ovarian Cancer Academy (OCA) is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment.

The OCA is a virtual career development and research training platform that currently consists of 13 Early-Career Investigator (ECI)/Designated Mentor pairs from different institutions, and one Academy Dean and one Assistant Dean. Three ECIs will be graduating in the fall of FY19 and three FY18 OCA-ECI/Designated Mentor awards will be made by September 2019. In addition, eight have Academy graduates continue to participate in the annual Academy meetings. Information about the Academy is available in the FY17 Ovarian Cancer Program Booklet at http://cdmrp.army.mil/ocrp/pbks/ocrppbk2017.pdf. The Academy Dean and Assistant Dean catalyze the growth and professional development of the ECIs in collaboration with their Designated Mentors, assess the progress of the ECIs, and facilitate communication and collaboration among all of the Academy members.

This FY19 Funding Opportunity is soliciting applications for an Academy Dean and Assistant Dean to lead the OCA for an anticipated start date in first quarter of FY20 – exact date to be determined. The Academy Dean and Assistant Dean (referred to as Academy Leadership) must be established ovarian cancer researchers, and can be at different institutions. Designated Mentors on FY19 Ovarian Cancer Academy – Early-Career Investigator Award applications and current Designated Mentors of Ovarian Cancer Academy – Early-Career Investigators (with the exception of those graduating in 2019) are not eligible to apply for this award. The Academy Leadership must demonstrate a strong record of mentoring and training junior investigators, a commitment to leadership, and the ability to objectively assess the progress of all of the ECIs in the OCA.

Responsibilities of the Academy Leadership include, but are not limited to:

- Act as a resource for all ECIs and Designated Mentors in the Academy over the 5-year period of performance as Academy Leadership.
- Facilitate communication and collaboration among all of the ECIs and Designated Mentors (including periodic interactive communication among all Academy members).
- Develop assessment criteria to evaluate the research progress made by all of the ECIs, as well as their career progression and sustainment as independent investigators in ovarian cancer research.
- Conduct collaborative ovarian cancer pilot project(s) that include Academy ECIs. These pilot projects should have the potential to improve collaboration within the Academy, as well as impact ovarian cancer research and/or ovarian cancer patients/survivors.
- Provide constructive critiques with the goal of advancing the research and professional careers of the ECIs and strengthening the mentorship of the Designated Mentors.
- Provide avenues to increase the visibility of ECIs within the ovarian cancer research and advocacy communities (e.g., peer review, conferences, editorial boards).
- Support the professional development to include lab management skills, of the ECIs into leading researchers through invited presentations by experts outside of the OCA.
- Plan and host an annual 1-day workshop and biennially, a multi-day workshop for all ECI/Designated Mentor pairs as well as Academy graduates to present their research, share knowledge, and develop collaborative efforts within the OCA.
- Invite and financially support the travel for OCA graduates to attend the annual meetings, including them as speakers and participants.
- Assemble an Advisory Board to the Academy to include Academy alumni.
The Ovarian Cancer Academy Dean and Assistant Dean (Leadership) Award is structured to support two Principal Investigators (PIs). The Academy Dean will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Assistant Dean will be identified as the Partnering PI. The collaboration between the Academy Dean and the Assistant Dean should be supported by complementary expertise and experience. Initiating and Partnering PIs each have different submission requirements, as described in Section II.D.2, Content and Form of the Application Submission; however, both PIs should contribute significantly to the development of the proposed research project. The application should clearly demonstrate that both PIs have equal levels of input on the proposed Academy Leadership and clearly define the components to be addressed by each to continue the success of ECIs. While it is up to the Academy Dean and the Assistant Dean to define their roles, both Academy Leaders should have interactions with the ECIs; acting as administrative support does not fulfill the intent of the Assistant Dean. If recommended for funding, each PI will be named to an individual award within the recipient organization.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for the Initiating PI (Academy Dean) and the Partnering PI (Assistant Dean) awards for the entire 5-year period of performance for the FY19 OCRP Ovarian Cancer Academy Dean and Assistant Dean (Leadership) Award will not exceed $1.75M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** April 30, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** July 17, 2019

**Sponsor Deadline:** July 31, 2019

### Department of Defense (DoD) Ovarian Cancer Research Program (OCRP): Clinical Development Award

The OCRP Clinical Development Award is intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.

The goal of this award mechanism is to accelerate the clinical introduction of medical products and technologies that target ovarian cancer biology. Near-term clinical impact is expected. Proof of concept demonstrating the potential utility of the proposed product or a prototype/ preliminary version of the proposed product should already be established; thus, preclinical studies in animals are not allowed. Small-scale clinical trials (Phase 0, Phase 1), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed. Relevant data, either published or unpublished, that support the study rationale are required.

New FY19 definition: A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Funded trials are required to post a copy of the informed consent form used to enroll subjects on a publicly available Federal website in accordance with Federal requirements described in 32 CFR 219.

Important aspects of the application to the FY19 OCRP Clinical Development Award:

- The application should demonstrate availability of, and accessibility to, a suitable human subject population or anatomical samples that will support a meaningful outcome for the study, discussion of feasibility of the proposed study, and how accrual goals will be achieved.
- The application should demonstrate documented availability of, and accessibility to, the drug/compound, device, and/or materials needed.
- The proposed study should include clearly defined and appropriate endpoints.
- The application should include a detailed statistical analysis plan, including a power analysis reflecting sample size projections that will clearly answer the objectives of the study.
- Applications must also include a transition plan (including potential funding and resources) showing how the result will progress to the next level of development (e.g., future clinical trials, delivery to the military or civilian market) after the completion of the OCRP award.
- Applications are encouraged to include diversity in their sample populations.

Optional Nested Early-Career Investigator: For Principal Investigators (PIs) that are proposing clinical trials, this FY19 OCRP Clinical Development Award mechanism is offering an optional nested Early-Career Investigator to foster the next generation of ovarian cancer investigators in the conduct of clinical trials. One Early-Career Investigator can be named within a given application, and the Early-Career Investigator must be within 5 years of his/her last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent at the full application submission deadline. The Early-Career Investigator must meet specific eligibility criteria as described in Section II.C, Eligibility Information. Applications that contain a nested Early-Career Investigator will qualify for a higher level of
funding as described under Section II.D.5, Funding Restrictions. The PI on the Clinical Development Award must mentor the nested Early-Career Investigator.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al. A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191.

Relevance to Military Health: The proposed research must be relevant to the healthcare needs of military Service members, Veterans, military beneficiaries, and/or the American public.

Funding Details: The anticipated direct costs budgeted for the entire period of performance for an FY19 OCRP Clinical Development Award will not exceed $600,000, and the anticipated direct costs budgeted for the entire period of performance for an FY19 OCRP Clinical Development Award with an optional nested Early-Career Investigator will not exceed $800,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. The Government reserves the right to fund an application at a lower funding level if it does not meet the eligibility criteria or intent of the optional feature.

Additional Details
LOI Deadline: April 30, 2019 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: July 17, 2019
Sponsor Deadline: July 31, 2019